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ABSTRACT 
 
It has been well established that motor symptoms in Parkinson’s disease (PD) are 
primarily associated with dopaminergic degeneration in the basal ganglia. However, symptoms 
which respond poorly to dopaminergic replacement, such as tremor, gait, and balance deficits, 
point to an alternative pathology to dysfunction of the basal ganglia. Over-activity of the 
cerebellum has been demonstrated in PD, however it is not entirely clear how the cerebellum 
might be affecting motor symptoms. A lack of consensus exists regarding how cerebellar over-
activity might be influencing PD tremor, and whether resting and postural tremor are 
differentially influenced by cerebellar dysfunction. It is also unclear how cerebellar over-activity 
might be affecting gait and balance deficits in PD, even though the cerebellum is an important 
subcortical structure for the control of gait and balance. Thus, the aim of the current thesis was to 
assess how cerebellar over-activity may be influencing symptoms which respond poorly to 
dopamine replacement in PD by inhibiting cerebellar activity using repetitive transcranial 
magnetic stimulation (rTMS). Additionally, a direct comparison was made between the effects of 
stimulation targeted to the medial versus lateral cerebellum with the aim to localize the effect of 
cerebellar over-activity. Fifty PD participants were randomly assigned to receive stimulation 
over either the medial cerebellum (n=20), lateral cerebellum (n=20) or sham stimulation (n=10). 
900 pulses at 1Hz were delivered at an intensity of 120% resting motor threshold determined 
from the first dorsal interosseous muscle representation in the primary motor cortex. Tremor was 
assessed quantitatively using a wireless finger accelerometer to record tremor. Balance was 
measured with objective, computerized protocols: modified clinical test of sensory integration 
and balance (m-CTSIB) and postural stability testing (PST). Spatiotemporal gait parameters were 
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measured quantitatively during self-paced walking. All assessments were performed before and 
after either real or sham stimulation. Resting tremor frequency was reduced in tremor-dominant 
individuals, regardless of whether stimulation was applied over the medial (p=0.024) or lateral 
(p=0.033) cerebellum, but not in the sham group. Additionally, inhibition of the cerebellum did 
not result in modulation of gait and balance outcome measures. Hence, dysfunction of the 
cerebellum may be a contributing factor to resting tremor, but not gait and balance deficits in PD. 
Importantly, the improvements in resting tremor occurred without detriment to gait or balance, 
demonstrating the therapeutic potential of this stimulation protocol. Low frequency rTMS over 
the medial or lateral cerebellum provides promise of an alternative treatment for resting tremor in 
PD, a symptom that is poorly responsive to dopaminergic replacement. 
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Chapter 1: Prologue 
 
Parkinson’s disease 
 
Degeneration of dopaminergic neurons in the basal ganglia is responsible for the motor 
symptoms of Parkinson’s disease (PD). This neurodegenerative disease is progressive in nature, 
and typically presents four cardinal movement symptoms: tremor, rigidity, bradykinesia and 
postural instability. Motor symptoms do not become present until the amount of dopaminergic 
loss is substantial, and beyond repair. Typically, motor symptoms appear once 50-60% of 
dopaminergic neurons in the substantia nigra are lost, and striatal dopamine is diminished by 80-
85% [1]. Without a cure for PD, treatments are focused on symptom management, allowing 
individuals to live more comfortably with the disease for a longer duration.  
The gold standard for treatment of PD symptoms is dopaminergic replacement therapy, 
which acts to supplement dopamine that has been lost in the basal ganglia [2–4]. Although this is 
an effective method of treatment, the benefits of the medication vary over time[4]. Prolonged 
treatment in this manner increases the susceptibility of the individual to a realm of negative side 
effects. One side effect is the wearing off phenomenon, which is associated with motor 
fluctuations and characterized by the appearance or worsening of motor symptoms occurring 
before a scheduled dose of dopaminergic medication[3,4]. As the required dose for management 
of motor symptoms becomes higher, so does the risk of developing dyskinetic movements in the 
head, limbs, trunk and respiratory muscles. Dyskinetic movements are characterized by 
involuntary, purposeless movements which occur during both rest and voluntary movements 
[2,4,5]. Therefore, dopaminergic replacement is an effective shorter-term therapy for improving 
symptoms of rigidity and bradykinesia, however, the medication is less effective at improving 
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tremor, and has no effect on postural stability or balance control. This makes evident the need to 
look for alternatives to pharmaceutical therapy for the treatment and management of PD motor 
symptoms. Alternatives such as techniques to stimulate brain activity have the potential to 
enhance our understanding of brain functions and thus, the development of more effective 
treatments for PD symptoms. 
Cortical Excitability and Transcranial Magnetic Stimulation 
 
Transcranial magnetic stimulation (TMS) has been investigated as a non-invasive 
treatment option for PD symptoms [6–11]. TMS induces electric currents in the brain by 
producing magnetic pulses which are able to pass through the skull with little impedance. These 
magnetic fields are produced from a rapid electric current which circulates within the stimulation 
coil resting on the scalp[12]. The electric currents induced in the cortex travel perpendicular to 
the magnetic field in the coil, meaning that cortical stimulation travels in a direction toward the 
centre of the cortex [13]. The induced electrical current has the ability to depolarize neurons, and 
generate action potentials within specific cortical areas. For depolarization of a neuron to occur, 
the induced electric current must be strong enough to pass through the neuronal 
membrane[12,14].  
TMS is an avenue for inducing electric currents within the cortex, where the effects 
essentially act through modulation of cortical excitability [12,15–17]. Stimulation at high 
frequencies (5Hz or above) induces facilitatory changes in cortical excitability, through what is 
thought to be long term potentiation (LTP) mechanisms[14,15]. Meanwhile, stimulation at low 
frequencies (1Hz or below) induces inhibitory changes in cortical excitability, through what is 
thought to be long term depression (LTD) mechanisms[14,15].  
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Long term potentiation is a use-dependent strengthening of a synapse, which can increase 
the excitatory post-synaptic potentials following stimulation for a duration of time beyond the 
period of activation [18,19]. A common form of LTP requires activation of NMDA receptors in 
the synapse during post-synaptic depolarization. This activation during the early phase of long 
term potentiation causes a rise of calcium ion concentration in the dendritic spine by allowing 
calcium ions to pass through the NMDA receptor channel. The increase in calcium ion 
concentration may be enough to trigger LTP alone, however other mediating factors, such a 
proteins may also contribute. An increase in the number of AMPA receptors at the synapse has 
also been demonstrated as an important component of LTP expression. The late phases of LTP 
require protein synthesis if the synaptic changes are to persist beyond 30-60 minutes. Synapses at 
which LTP occurs undergo structural changes to permit late phase (long lasting) changes in 
excitability. Synaptic changes include the growth of dendritic spines, enlargement of existing 
spines, as well as either growth of post-synaptic densities or splitting to form two functional 
synapses[19].  Long term potentiation mechanisms differ at mossy fibre synapses, as well as 
cerebellar parallel fibre synapses, in that activation of NMDA receptors is not required. It is 
instead a rise in presynaptic calcium ions and the activation of presynaptic receptors by 
glutamate which plays a strong facilitatory role in mossy fibre LTP. However the need for new 
protein synthesis for late phase LTP is a common factor [19], and becomes important when 
lasting changes in cortical excitability are desired.   
In contrast, long term depression refers to a decrease in synaptic strength which is 
thought to either prevent a saturation of LTP, by placing a synapse in a temporary state of 
heightened responsiveness, or to serve as a replacement for information previously associated 
with LTP. LTD has also been suggested to function as an amplification mechanism, allowing 
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signals from surrounding potentiated synapses to become of greater strength [19,20]. NMDA 
receptor activation and a rise in post-synaptic calcium ions also play a key role in a common 
form of LTD, however it is the stimulation intensity which dictates the excitability changes. It 
has been suggested that the sub-unit composition of the NMDA receptors is regulated by activity 
at the synapses, and thus governs the expression of either LTD or LTP. While an increase in 
AMPA receptors contributes to LTP, it is a decrease in AMPA receptors that accompanies LTD 
expression [19]. Given that cerebellar synapses lack NMDA receptor expression[20,21], there 
exists three post-synaptic events which must occur for LTD induction in the cerebellum. First, 
the climbing fibres initiate a large calcium ion influx by causing post synaptic depolarization that 
is sufficient to activate voltage-gated calcium ion channels in the dendrites. Second, parallel 
fibres activate metabotropic receptors and non-NMDA excitatory amino acid receptors. Finally, 
an influx of sodium ions occurs via AMPA receptors (activated by parallel fibres) and voltage-
gated sodium ion channels. Importantly, activation of both parallel fibres and climbing fibres (or 
directly Purkinje neurons) are necessary for the induction of LTD in the cerebellum[20,21]. LTD 
has been suggested to be related to motor performance errors, such that a synapse is signalled to 
be weakened following an error. According to existing models, it is the climbing fibres which 
dictate changes in synaptic strength[20]. 
Modulation of synaptic strength, and thus, cortical excitability, requires repeated 
activation or inhibition of the associated cortical area[6], particularly if the changes are intended 
to be long-lasting. The induced effects of stimulation on a cortical area is dependent on many 
parameters: the frequency or rate at which the pulses are delivered, the intensity of the stimulus, 
the duration of stimulation period (total number of pulses) and the cortical location of 
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stimulation[22].  Therefore, the stimulation effects found will be reflective of the parameters 
chosen.  
Repetitive transcranial magnetic stimulation (rTMS) 
 
Repetitive transcranial magnetic stimulation (rTMS) involves repetitive pulses being 
delivered, and allows for cortical changes in excitability to outlast the period of stimulation. With 
repeated sessions of stimulation, it is possible that the cumulative effects of rTMS may interact 
directly with the mechanisms of cortical plasticity, and prolong the period for which the cortical 
changes due to LTD and LTP exist beyond the period of stimulation.  Studies have suggested 
that the threshold for inducing inhibitory effects in the cortex is lower than that of facilitatory 
effects, and the inhibitory effects were able to accumulate quicker[23]. In a review article by 
Fregni et al. (2005), it was found that the studies showing significant and long lasting effects  
were the protocols that demonstrated immediate benefits following an acute period of 
stimulation. This might suggest that immediate motor benefits are predictive of long lasting 
benefits[16], and could suggest the potential efficacy of a stimulation protocol for use as a 
therapy.  
What is known about rTMS as a treatment in PD? 
 
Several studies have explored the effectiveness of rTMS for PD. For example, Lomarev 
et al. (2006) found that two rTMS sessions per week for a total of eight weeks was able to 
significantly improve gait speed during a ten metre walking task, and upper limb bradykinesia 
for individuals with PD[6]. These motor improvements persisted for at least one month following 
the end of the stimulation sessions. During each stimulation session, 300 magnetic pulses at 
100% motor threshold and 25Hz was delivered to each of four cortical targets: left and right 
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abductor pollicis projection in the motor cortex, as well as left and right dorsolateral prefrontal 
cortex[6]. In another study by Hamada et al, 1000 magnetic pulses were delivered in trains of 50 
stimuli at 5Hz and 110% active motor threshold of the right tibialis anterior muscle[7]. Sessions 
were performed once each week for a total of eight weeks, with the pulses being applied over the 
supplementary motor area. This group found modest improvements in Unified Parkinson’s 
Disease Rating Scale motor sub-section (UPDRS-III) scores following the intervention, with 
changes lasting up to 4 weeks beyond culmination of treatment[7]. Other protocols, such as 
stimulation Monday to Friday, for two weeks (ten total sessions) over the vertex demonstrated no 
therapeutic potential[8]. Arias et al administered 100 pulses in trains of 50 stimuli at 1Hz and an 
intensity of 90% resting motor threshold. This group determined the protocol to provide benefits 
not greater than placebo on the performance of a walking task, grooved pegboard and total 
UPDRS scores[8]. Though the examples provided are not comprehensive of all rTMS 
therapeutic protocols, it is clear that a stimulation target alternative to the motor cortex may 
provide some additional benefits. 
Neural Circuitry Related to rTMS Application in PD 
 
The Basal Ganglia in Parkinson’s disease 
 
Arguably the most important property of TMS is the stimulation target, which requires a 
great understanding of cortical circuitry. The primary brain structure implicated in the 
pathophysiology of PD is the basal ganglia, more specifically the degeneration of dopaminergic 
producing neurons in the substantia nigra pars compacta. Dopamine is a vital neurotransmitter 
that is implicated in the basal ganglia pathways responsible for movement production; the lack of 
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neurotransmitter in the disease state results in altered connectivity within these pathways, 
ultimately affecting movement output.  
There are two main pathways within the basal ganglia that modulate movement: the 
direct pathway, associated with promoting movement production, and the indirect pathway, 
associated with the inhibition of movement production[24–26]. Both pathways originate from 
populations of neurons in the striatum which express opposing types of dopaminergic receptors. 
Activation of D1 receptors in the striatum produces an overall excitatory effect on the neurons 
associated with the direct path, while activation of D2 receptors produces an overall inhibitory 
effect on neurons of the indirect path[25]. In the direct path, cortical information from the 
striatum is transmitted directly to the globus pallius internus and the substantia nigra pars 
reticulata, the output nuclei of the basal ganglia, via an inhibitory GABA-ergic projection. In 
contrast, the indirect path transmits cortical signals from the striatum indirectly through an 
inhibitory GABA-ergic projection from the globus pallidus externus to the subthalamic nucleus, 
and an excitatory projection from the subthalamic nucleus to the output nuclei[24,25]. Signals 
from both pathways relay in the thalamus before being transmitted back to the cerebral cortex 
and brainstem to exert effects on movement production.  
Dopaminergic loss in the substantia nigra pars compacta has a major effect on the 
connectivity of these pathways, and thus, movement production. The lack of the neurotransmitter 
dopamine results in decreased activity within the striatal neurons of the direct pathway. 
Meanwhile, a lack of dopamine promotes increased activity in the striatal neurons of the indirect 
pathway. The increased activity results in increased inhibition of the globus pallidus externus, 
coupled with disinhibition of the subthalamic nucleus which potentiates to increased excitation 
of the basal ganglia output nuclei [25]. Taken together, decreased activity from the direct 
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(movement producing) pathway, in conjunction with increased activity in the indirect (movement 
inhibiting) pathway, results in a net inhibitory output from the basal ganglia nuclei. Thus, 
dopaminergic loss is associated with an overall reduction in the production of movement [24,25].  
This makes the basal ganglia a logical target for the application of magnetic stimulation 
due to the role of the structure in the pathophysiology of the disease, however, there are several 
issues with using the basal ganglia as a target. First, due to the depth of the basal ganglia within 
the brain, the stimulation intensity required to reach an adequate depth would be above the range 
of tolerable stimulation, or the capabilities of TMS devices. Second, if such an intensity was 
attained to reach the depth of the basal ganglia, the electrical current induced in the cortex would 
be very diffuse, not allowing for focal stimulation. Finally, areas superior to the basal ganglia 
within the cortex would be stimulated as the electrical current travelled toward the structure, not 
allowing for the basal ganglia to be targeted with TMS in isolation. It has now been made 
evident that a more superficial structure, alternative to the basal ganglia, must be chosen as a 
stimulation target.  
 
The Cerebellum in Parkinson’s disease 
As previously mentioned, the onset of motor symptoms in PD does not occur 
immediately upon the initiation of degeneration of dopaminergic neurons, but after a substantial 
loss. This might suggest the existence of a compensatory mechanism which functions to preserve 
normal basal ganglia functioning and delay the onset of symptoms[27]. There is increasing 
evidence of multi-synaptic anatomical connections that exist between the cerebellum and the 
basal ganglia [28–30].  
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The dentate nucleus projects to both the striatum and globus pallidus externus of the basal 
ganglia. A disynaptic projection to the striatum, by way of the thalamus, originates in both motor 
and non-motor areas of the dentate nucleus[28–30]. This suggests that the cerebellum might 
influence this pathway, which is implicated in information processing in the basal ganglia. The 
subthalamic nucleus of the basal ganglia also has a topographically organized disynaptic 
projection to the cerebellar cortex through the pontine nuclei. This connection enables the 
involvement of integration of the basal ganglia-cerebellar functions on both a motor and non-
motor level[28–30]. The subthalamic neurons project to both the crus II posterior (area of the 
cerebellum which receives input from regions of the prefrontal cortex and frontal eye fields), as 
well as the sensorimotor area of lobule VIIB (an area which receives input from the primary and 
premotor cortices)[28]. These identified reciprocal connections between the basal ganglia and the 
cerebellum create an anatomical basis to question the involvement of the cerebellum in the 
pathology of PD and the associated motor symptoms.  
The presence of dopamine D1-3 receptors in the cerebellum allows this structure to 
receive dopaminergic innervation from the ventral tegmental area/ substantia nigra pars 
compacta[31]. Knowing that the substantia nigra pars compacta is the primary site of 
dopaminergic loss in PD, it is no surprise that expression levels of D1-3 dopamine receptors are 
consequently altered in the cerebellum. Dopamine receptors, along with the mRNA for tyrosine 
hydrolase and dopamine active transporter, are present in the cerebellar vermis (lobules 9 and 
10). Since mRNA is only associated with neural cell bodies and dendrites, the presence of 
dopamine producing mRNA in the cerebellum suggests that these gene products must exist 
intrinsically within the cerebellum[31].  Thus, the presence of dopamine within the cerebellum 
may help explain the connectivity and signalling between the basal ganglia and cerebellum.  
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Post-mortem analysis of the cerebellum in PD patients showed decreased levels of D1 
and D3 dopamine receptor mRNA in lobule 9, along with decreased levels of tyrosine hydrolase 
and dopamine receptor mRNA in lobule 10 [31]. Similarly, lesions of the paravermal cerebellum 
increases receptor D1 levels in the contralateral striatum, suggesting that cerebellar nuclear and 
cortical projections modulate D1 receptor expression of the striatal direct pathway[31]. Within 
the striatum, a co-expression of dopamine D1-D3 receptors exists within the same cells, where 
the D1 and D3 receptors exert opposing effects on the D2 receptors. The specific reduction of D1 
and D3 receptors in the cerebellum, without modification in D2 receptor expression, suggests 
that the dopamine receptors of the cerebellum behave similarly to those in the striatum[31].  
Degeneration of striatal dopaminergic neurons would therefore be related to dysfunction not only 
in the basal ganglia, but also in the basal ganglia-thalamic and cerebellum-thalamic connections. 
This might suggest that this pathological damage in the cerebellum, that is unique to PD, might 
contribute to motor symptom generation.  
There are characteristic changes that occur in the cortical connectivity patterns in PD: 
hyper-metabolism in the striatum, thalamus, pons and cerebellum, together with hypo-
metabolism in the supplementary motor area, premotor and parieto-occipital association 
areas[28]. Increased activation of the cerebellum in PD compared to controls is consistently 
present not only throughout motor task execution and motor learning tasks, but also at 
rest[28,30,32]. Functional magnetic resonance imaging shows that in predominantly 
akinetic/rigid PD patients, the amount of spontaneous cerebellar activation at rest is heightened. 
In these individuals, there were weakened connections between the striatum-cortex and striatum-
cerebellum, paired with increased connectivity between the cortex and cerebellum during self-
initiated movements[28]. It has been suggested that the hyperactivity in the cerebellum might be 
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a compensatory strategy to help overcome the dysfunction in the basal ganglia[28,32]. 
Understanding the connection between the cerebellum and basal ganglia may lead to potential 
treatment options for those symptoms associated with PD that are not responsive to 
dopaminergic treatment.  
In order for the hyper-activation and connectivity changes in the cerebellum to be 
considered a compensatory mechanism, the responses of the cerebellum should exhibit 
physiological adaptations that act to counterbalance the abnormal functioning of the basal 
ganglia. For example, the supplementary motor area is a main input region in the basal ganglia 
motor circuit, where decreased activity in PD is thought to be the result of inadequate striato-
thamalo-cortical facilitation[28,32]. Since the supplementary motor area is heavily implicated in 
initiating internally generated movements, pairing this underactivity in the striato-thalamo-
cortical loop with dopamine depletion could provide a mechanism to explain akinesia in PD. 
Interestingly, where hyper-activity was found in the cerebellum, individuals with PD were able 
to complete motor tasks in a manner comparable to healthy participants[28]. This might suggest 
that the increased activity in the cerebello-thalamo-cortical loop compensated for the lack of 
activity in the striato-thalamo-cortical loop in such a way that motor function was able to remain 
near normal[32]. To further support this notion of compensation, activity or connectivity of the 
cerebello-thalamo-cortical loop demonstrated a positive correlation with UPDRS scores (a 
clinical assessment scale), while that of the striato-thalamo-cortical loop demonstrated a negative 
correlation[28]. Recruitment of the cerebello-thalamo-cortical loop increases with PD 
progression, suggesting that as the impairment in the striato-thamalo-cortical loop becomes 
greater, activity in the latter becomes more important for compensation.  
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On the opposing side, increased cerebellar activity could be seen as negatively 
contributing to the pathophysiology of PD symptoms. While the cerebello-thalamo-cortical loop 
may serve to compensate for akinetic/rigid symptoms, it may actively contribute to other 
symptoms, such as tremor, poor balance and gait impairments. Given that the connection 
between the basal ganglia and the cerebellum is reciprocal, hyperactivity in the cerebellum could 
stem from the inability of the basal ganglia to suppress activity of inappropriate or abnormal 
output of circuits.[30]. The subthalamic nucleus, or the “driving force” of the basal ganglia[26], 
has significantly heightened activity in PD. The subthalamic nucleus output is excitatory 
(glutamatergic), and the activity can be described in PD as abnormal bursting and oscillatory in 
nature. Propagation of the chronically increased excitatory drive from the subthalamic nucleus to 
the cerebellum via the pontine nuclei could account for the overactivity of the cerebellum. This 
has been confirmed in rat brains, whereby activation of neurons in the deep cerebellar nuclei 
occurs following high frequency stimulation of the subthalamic nucleus[30]. Therefore, altered 
cerebello-thalamo-cortical circuit activity might actually contribute to PD symptoms, and help to 
explain why not all symptoms are responsive to dopaminergic replacement therapy, or the result 
of striatal dopaminergic degeneration. 
The Contribution of the Cerebellum to Motor Symptoms in PD 
 
Cerebellar Contributions to Tremor Generation 
 
Parkinsonian tremor exists in the most distal extremities, and can occur both during rest 
or movement. Resting tremor persists at 4-5 Hz, while postural tremor is characterized by a 
higher frequency of 8-12 Hz[27]. Dysfunction of the basal ganglia and striatal dopamine 
degeneration are more strongly linked with the bradykinesia and rigidity associated with PD, and 
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seem to be less implicated in the generation of tremor[27]. Given that peripheral deafferentation 
fails to modulate resting tremor, it can be concluded that the underlying mechanism must be 
related to a more central abnormality[28]. There is increasing evidence that the cerebello-
thalamo-cortical pathway contributes to the pathophysiology of tremor. There is a characteristic 
tremor-related pattern of cortical activation in PD, consisting of concurrent increases in 
activation of the cerebellum, motor cortex and putamen. This pathway demonstrates a correlation 
with clinical tremor ratings, but not that of akinesia or rigidity. Similarly, activity in this cortical 
pattern has been found to be elevated in tremor-dominant PD, while not in akinetic-rigid PD, 
suggesting specific involvement in the generation of tremor. Further, it has been shown that deep 
brain stimulation (DBS) of the ventrolateral nucleus reduces the activity of this pattern, while 
DBS of the subthalamic nucleus reduces both tremor and akinetic/rigid activity 
simultaneously[28]. This further supports the notion suggesting that tremor may be generated by 
a metabolic network which is distinct from that of akinesia/rigidity. It has long been thought that 
tremor may be generated by neural mechanisms which are actively working to compensate for 
akinesia and rigidity[28]. This could help to explain the differential symptomology between 
individuals with PD.  
Individuals with PD who experience tremor symptoms demonstrate a strengthened 
functional connectivity between the basal ganglia and the cerebello-thalamo-cortical pathway, 
suggesting this pathological interaction may result in tremor generation. Tremor reset is a tool 
used to confirm the contribution of a specific stimulated brain area to the generation or 
transmission of tremor[33]. The cerebello-thalamo-cortical pathway allows stimulation effects 
from TMS on the cerebellum to be transmitted to the thalamus, basal ganglia and primary motor 
cortex, which interrupts the ongoing tremor drive, resulting in a tremor reset. Activity in the 
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basal ganglia is the likely trigger to tremor generation in the cerebello-thalamo-cortical circuit, 
specifically dysfunction in the vermis/paravermis region. Reduced excitability in the cerebello-
thalamo-cortical pathway might allow for abnormal neuronal activities to occur at the thalamus 
and primary motor cortex, which is the site of integration of cerebellar and basal ganglia 
loops[34].  
It is debated whether the cerebellum contributes to both rest and postural tremor, or 
whether the cereblello-thalamo-cortical loop may have a more significant effect on one specific 
form of tremor. A study using paired-pulse TMS over the cerebellum and primary motor cortex 
found that the amount of cerebellar inhibition in the primary motor cortex was proportional to 
the tremor reset index[33]. While this protocol did not alter the frequency of tremor, it did result 
in the reset of postural, but not resting, tremor. It has been suggested that pathways for 
generation of resting and postural tremor originate from differing cortical areas. This notion can 
be supported based on the key differences in the frequency between resting and postural tremor 
(rest tremor has a lower frequency) and the stimulation targets which produced the highest 
tremor reset index[33]. While stimulation of the primary motor cortex reset both varieties of 
tremor, the reset index was higher for postural tremor. In contrast, cerebellar stimulation only 
reset postural tremor, having no effect on resting tremor. Ni et al suggested the isolated 
involvement of the cerebellum in postural tremor, with the effects likely mediated by the basal 
ganglia and not the primary motor cortex following stimulation.  
Pallidal dopamine depletion levels are a strong indicator of tremor severity, and does not 
seem to be related to striatal dopamine depletion[34]. While the basal ganglia does have a role in 
the generation of tremor, it is the cerebello-thalamo-cortical circuit that drives the tremor pattern 
on a cycle-by-cycle basis. This property of tremor generation may help to explain why tremor-
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dominant PD have reportedly better symptom prognosis, characterized by lower risk of 
dyskinesia and motor fluctuations in response to dopaminergic replacement therapy. In 
comparison to akinetic/rigid PD, it is possible that tremor-dominant PD is less due to basal 
ganglia pathologies, and is more associated with abnormalities associated with the cerebello-
thalamo-cortical circuit[27]. Whether this is true for both postural and rest tremor or specifically, 
postural tremor is still debated in research.  
Cerebellar Contributions to Gait Disturbances 
 
The cerebello-thalamo-cortical pathway has also been suggested to play a role in the 
pathophysiology of gait disturbances in PD.  While gait parameters such as velocity, stride length 
and stride time have demonstrated improvements related to dopaminergic therapy, other 
parameters such as step frequency (cadence) and double limb support time appear to be non-
responsive to dopamine replacement. Dopamine may benefit gait indirectly by reducing the 
effects of rigidity and bradykinesia , without effectively improving all aspects of gait[35]. This 
suggests the involvement of separate pathways underlying the pathology of gait disturbances in 
PD, where spatial aspects of gait seem more related to dopamine, and thus the involvement of the 
basal ganglia, than do temporal aspects of gait[36–38].   
Double limb support time is thought to reflect postural stability during gait. This gait 
parameter is increased in PD, indicative of impaired dynamic balance control mechanisms [36–
38]. Decreased acetylcholinesterase activity in the midbrain and cerebellum were found to be 
correlated with the severity of balance and gait impairments in PD. During gait, it has been 
suggested that hyper-activation in the vermis may act to compensate for a lack of lateral gravity 
shift[28]. This property, likely caused by hypo-activation in the left cerebellar hemisphere, is 
thought to be responsible for the small, shuffling steps characteristic of individuals with PD[28]. 
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Thus, it may be possible to find benefits in gait through modifying cortical activity in the 
cerebellum. 
The pedunculopontine nucleus demonstrated connectivity with the cerebellum in healthy 
subjects and individuals with PD who lack severe gait disturbances [28]. In PD who had severe 
gait disturbances, this connection did not exist. It was found that when DBS was applied to the 
pedunculopontine nucleus, a consequent increase in blood flow within the cerebello-thalamo-
cortical pathway resulted[28]. This might suggest that the cerebello-thalamo-cortical pathway 
may be an effective stimulation target to improve gait disturbances in PD.  
Cerebellar Contributions to Balance Control and Postural Instability 
 
An important intermediary to understanding how the cerebellum influences gait 
disturbances is to first understand its contributions to balance. There is increasing evidence that 
postural instability in PD cannot be attributed to only the loss of striatal dopaminergic neurons. 
The vermis and fastigial nuclei are important structures in the cerebellum which contribute to 
balance control. These regions are implicated in exerting control over extensor muscle tone in 
order to maintain upright balance and stance. Also under the control of these regions is the 
vestibular and reticular nuclei, which act to modulate the rhythmic activation of both flexor and 
extensor muscle groups. The cerebellum also utilizes sensory feedback from the limbs to exert 
postural changes for balance control.  
Impairments in sensory integration have been suggested to have a negative impact on 
balance in PD[39–43], such that deficits in proprioceptive processing require individuals to rely 
mainly on visual feedback for balance control. It has been suggested that vision dependence in 
PD could be a cerebellar mechanism which allows utilization of relatively intact cerebellar 
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pathways in order to avoid the dysfunctional basal ganglia. Individuals with PD therefore rely on 
an intact visually guided network, that is the cerebellum[27]. This heightened reliance on vision 
puts individuals with PD at a greater risk of loss of balance when vision is compromised or not 
available, such as in dark environments[43,44]. It is possible that altering the activity within the 
cerebellum-basal ganglia connections may improve sensory integration, and thus postural 
stability, by decreasing the reliance on vision.  
There seems to exist a PD-specific effect related to thalamic cholinergic denervation such 
that the ability to integrate sensory information for balance control is negatively affected[45]. 
The pedunculopontine complex sends cholinergic inputs to the thalamus, cerebellum, brainstem 
nuclei, basal ganglia and spinal cord[45]. Neurons in the thalamus which respond to 
proprioceptive stimuli, are functionally related with magnocellular neurons receiving cerebellar 
projections in the ventrolateral posterior nucleus. This might suggest that some level of 
cerebellar modulation of proprioceptive information might occur in the thalamus neurons before 
they are sent to motor cortical areas[46]. When comparing individuals with PD who experience 
falls against those that do not, there is not a significant difference in the level of striatal 
dopaminergic degeneration. Interestingly, PD who experience falls have significantly decreased 
pedunculopontine (thalamic) cholinergic innervation [43]. The level of cholinergic denervation 
was found to be associated both with poor balance during assessments, as well as increased 
UPDRS scores. Treatment with acetylcholinesterase significantly reduces the number of falls, 
suggesting that degeneration of the pedunculopontine cholinergic system might be associated 
with contributing to the pathology of postural instability[45]. Thus, modifying activity within the 
cerebello-thalamo-cortical loop has the potential to improve symptoms of postural instability in 
PD.  
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Modulation of the Cerebello-Thalamo-Cortical Pathway 
  
Thesis Objective 
 
The need to investigate the role of the cerebellum in the generation of tremor, as well as 
gait and balance deficits has been made evident. The current thesis will aim to understand how 
the cerebellum might be influencing these symptoms which respond poorly to dopaminergic 
replacement, by modulating cerebellar over-activity using a repetitive transcranial magnetic 
stimulation (rTMS) protocol. Direct comparisons are made between the effects on motor 
symptoms of an inhibitory rTMS protocol targeted at the medial versus lateral cerebellum, 
controlled by a sham stimulation group. Chapter two aims to investigate how the cerebellum 
might be differentially affecting resting and postural tremor in PD, with the use of a wireless 
finger accelerometer to objectively measure tremor before and after rTMS. Chapter three goes 
further to investigate whether cerebellar over-activity might also be influencing gait and balance 
deficits in PD, by using objective and computerized assessments of balance and spatiotemporal 
gait parameters before and after rTMS. Finally, chapter four provides a general discussion, 
offering a summary of the findings and implications for guiding future research toward further 
understanding the cerebellum in Parkinson’s disease.   
 19 
 
References 
[1] Wirdefeldt K, Adami H-O, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology 
of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011;26:S1–58. 
[2] Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: 
clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007;83:384–8. 
[3] Pahwa R, Lyons KE. Levodopa-related wearing-off in Parkinson’s disease: identification 
and management. Curr Med Res Opin 2009;25:841–9. 
[4] Almeida QJ, Hyson HC. The Evolution of Pharmacological Treatment for Parkinson ’ s 
Disease. Recent Pat CNS Drug Discov 2008;3:50–4. 
[5] Rothwell J. Transcranial magnetic stimulation as a method for investigating the plasticity 
of the brain in Parkinson ’ s Disease and dystonia. Parkinsonism Relat Disord 
2007;13:417–20. 
[6] Lomarev MP, Kanchana S, Bara-Jimenez W, Iyer M, Wassermann EM, Hallett M. 
Placebo-controlled study of rTMS for the treatment of Parkinson’s disease. Mov Disord 
2006;21:325–31. 
[7] Hamada M, Ugawa Y, Tsuji S. High-frequency rTMS over the supplementary motor area 
for treatment of Parkinson’s disease. Mov Disord 2008;23:1524–31. 
[8] Arias P, Vivas J, Grieve KL, Cudeiro J. Controlled trial on the effect of 10 days low-
frequency repetitive transcranial magnetic stimulation (rTMS) on motor signs in 
Parkinson’s disease. Mov Disord 2010;25:1830–8. 
[9] Khedr EM, Farweez HM, Islam H. Therapeutic effect of repetitive transcranial magnetic 
stimulation on motor function in Parkinson’s disease patients. EurJNeurol 2003;10:567–
72. 
[10] Lefaucheur J-P, Drouot X, Von Raison F, Ménard-Lefaucheur I, Cesaro P, Nguyen J-P. 
Improvement of motor performance and modulation of cortical excitability by repetitive 
transcranial magnetic stimulation of the motor cortex in Parkinson’s disease. Clin 
Neurophysiol 2004;115:2530–41. 
[11] Benninger, D.H., Berman, B.D., Houdayer, E., Pal, N., Luckenbaugh, D.A., Schneider, L., 
Miranda, S. & Hallett M. Intermittent theta-burst transcranial magnetic stimulation for 
treatment of Parkinson disease. Neurology 2011;76:601–9. 
[12] Arias-Carrión O. Basic mechanisms of rTMS: Implications in Parkinson’s disease. Int 
Arch Med 2008;1:2. 
[13] Hallett M. Transcranial magnetic stimulation: a primer. Neuron 2007;55:187–99. 
 20 
 
[14] Kobayashi M, Pascual-leone A. Transcranial magnetic stimulation in neurology. Lancet 
Neurol 2003;2:145–56. 
[15] Cantello R, Tarletti R, Civardi C. Transcranial magnetic stimulation and Parkinson ’ s 
disease. Brain Res Rev 2002;38:309–27. 
[16] Fregni F, Simon DK, Wu a, Pascual-Leone a. Non-invasive brain stimulation for 
Parkinson’s disease: a systematic review and meta-analysis of the literature. J Neurol 
Neurosurg Psychiatry 2005;76:1614–23. 
[17] Rossini PM, Rossi S. Transcranial magnetic stimulation: diagnostic, therapeutic, and 
research potential. Neurology 2007;68:484–8. 
[18] Madison D V, Malenka RC, Nicoll R a. Mechanisms underlying long-term potentiation of 
synaptic transmission. Annu Rev Neurosci 1991;14:379–97. 
[19] Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron 2004;44:5–
21. 
[20] Massey P V, Bashir ZI. Long-term depression: multiple forms and implications for brain 
function. Trends Neurosci 2007;30:176–84. 
[21] Linden DJ. Long-term synaptic depression in the mammalian brain. Neuron 1994;12:457–
72. 
[22] Siebner HR, Rothwell J. Transcranial magnetic stimulation: new insights into 
representational cortical plasticity. Exp Brain Res 2003;148:1–16. 
[23] Filipović SR, Rothwell JC, Bhatia K. Slow (1 Hz) repetitive transcranial magnetic 
stimulation (rTMS) induces a sustained change in cortical excitability in patients with 
Parkinson’s disease. Clin Neurophysiol 2010;121:1129–37. 
[24] DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch 
Neurol 2007;64:20–4. 
[25] Smith Y, Bevan MD, Shink E, Bolam JP. Microcircuitry of the direct and indirect 
pathways of the basal ganglia. Neuroscience 1998;86:353–87. 
[26] Strafella AP, Vanderwerf Y, Sadikot AF. Transcranial magnetic stimulation of the human 
motor cortex influences the neuronal activity of subthalamic nucleus. Eur J Neurosci 
2004;20:2245–9. 
[27] Lewis MM, Galley S, Johnson S, Stevenson J, Huang X, Mckeown MJ. The Role of the 
Cerebellum in the Pathophysiology of Parkinson ’ s Disease. Can J Neurol Sci 
2013;40:299–306. 
 21 
 
[28] Wu T, Hallett M. The cerebellum in Parkinson’s disease. Brain 2013;136:696–709. 
[29] Carrillo F, Palomar FJ, Conde V, Diaz-corrales FJ, Porcacchia P, Fernández-del-olmo M, 
et al. Study of Cerebello-Thalamocortical Pathway by Transcranial Magnetic Stimulation 
in Parkinson ’ s Disease. Brain Stimul 2013;6:582–9. 
[30] Kishore A, Meunier S, Popa T. Cerebellar influence on motor cortex plasticity : behavioral 
implications for Parkinson ’ s disease. Front Neurol 2014;5:1–8. 
[31] Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the 
cerebellum in normal individuals and patients with Parkinson’s disease examined by RT-
PCR. Eur J Neurosci 2003;18:2668–72. 
[32] Yu H, Sternad D, Corcos DM, Vaillancourt DE. Role of hyperactive cerebellum and 
motor cortex in Parkinson ’ s disease. Neuroimage 2007;35:222–33. 
[33] Ni Z, Pinto AD, Lang AE, Chen R. Involvement of the Cerebellothalamocortical Pathway 
in Parkinson Disease. Ann Neurol 2010;68:816–24. 
[34] Helmich RC, Janssen MJR, Oyen WJG, Bloem BR, Toni I. Pallidal Dysfunction Drives a 
Cerebellothalamic Circuit into Parkinson Tremor. Ann Neurol 2011;69:269–81. 
[35] Foreman KB, Wisted C, Addison O, Marcus RL, Lastayo PC, Dibble LE. Improved 
Dynamic Postural Task Performance without Improvements in Postural Responses: The 
Blessing and the Curse of Dopamine Replacement. Parkinsons Dis 2012;2012:692150. 
[36] Rochester L, Baker K, Nieuwboer A, Burn D. Targeting dopa-sensitive and dopa-resistant 
gait dysfunction in Parkinson’s disease: selective responses to internal and external cues. 
Mov Disord 2011;26:430–5. 
[37] Lord S, Baker K, Nieuwboer A, Burn D, Rochester L. Gait variability in Parkinson’s 
disease: an indicator of non-dopaminergic contributors to gait dysfunction? J Neurol 
2011;258:566–72. 
[38] Almeida QJ, Frank JS, Roy E a, Patla AE, Jog MS. Dopaminergic modulation of timing 
control and variability in the gait of Parkinson’s disease. Mov Disord 2007;22:1735–42. 
[39] Tan T, Almeida QJ, Rahimi F. Proprioceptive deficits in Parkinson’s disease patients with 
freezing of gait. Neuroscience 2011;192:746–52. 
[40] Caudron S, Guerraz M, Eusebio A, Gros J, Azulay J, Vaugoyeau M. Evaluation of a 
visual biofeedback on the postural control in Parkinson ’ s disease. Clin Neurophysiol 
2014;44:77–86. 
[41] Vaugoyeau M, Hakam H, Azulay J. Proprioceptive impairment and postural orientation 
control in Parkinson ’ s disease. Hum Mov Sci 2011;30:405–14. 
 22 
 
[42] Tagliabue M, Ferrigno G, Horak F. Effects of Parkinson’s disease on proprioceptive 
control of posture and reaching while standing. Neuroscience 2009;158:1206–14. 
[43] Horak FB. Postural orientation and equilibrium: what do we need to know about neural 
control of balance to prevent falls? Age Ageing 2006;35 Suppl 2:ii7–11. 
[44] Jacobs J V, Horak FB. Abnormal proprioceptive-motor integration contributes to 
hypometric postural responses of subjects with Parkinson’s disease. Neuroscience 
2006;141:999–1009. 
[45] Muller MLTM, Albin RL, Kotagal V, Koeppe RA, Scott PJH, Frey KA, et al. Thalamic 
cholinergic innervation and postural sensory integration function in Parkinson ’ s disease. 
Brain 2013;136:3282–9. 
[46] Popa T, Velayudhan B, Hubsch C, Pradeep S, Roze E, Vidailhet M, et al. Cerebellar 
Processing of Sensory Inputs Primes Motor Cortex Plasticity. Cereb Cortex 2013;23:305–
14. 
[47] Bologna M, Di Biasio F, Conte A, Iezzi E, Modugno N, Berardelli A. Effects of cerebellar 
continuous theta burst stimulation on resting tremor in Parkinson’s disease. Parkinsonism 
Relat Disord 2015;21:1–6. 
[48] Minks E, Mareček R, Pavlík T, Ovesná P, Bareš M. Is the cerebellum a potential target for 
stimulation in Parkinson’s disease? Results of 1-Hz rTMS on upper limb motor tasks. 
Cerebellum 2011;10:804–11. 
[49] Koch G, Brusa L, Carrillo F, Lo Gerfo E, Torriero S, Oliveri M, et al. Cerebellar magnetic 
stimulation decreases levodopa-induced dyskinesias in Parkinson disease. Neurology 
2009;73:113–9. 
[50] Popa T, Russo M, Meunier S. Long-lasting inhibition of cerebellar output. Brain Stimul 
2010;3:161–9. 
[51] Fierro B, Giglia G, Palermo A, Pecoraro C, Scalia S, Brighina F. Modulatory effects of 1 
Hz rTMS over the cerebellum on motor cortex excitability. Exp Brain Res 2007:440–7. 
[52] Langguth B, Eichhammer P, Zowe M, Landgrebe M, Binder H, Sand P, et al. Modulating 
cerebello-thalamocortical pathways by neuronavigated cerebellar repetitive transcranial 
stimulation ( rTMS ). Clin Neurophysiol 2008;38:289–95. 
[53] Hardwick RM, Lesage E, Miall RC. Cerebellar transcranial magnetic stimulation: The role 
of coil geometry and tissue depth. Brain Stimul 2014;7:643–9. 
[54] Ugawa Y, Uesaka Y, Terao Y, Hanajima R, Kanazawa I. Magnetic stimulation over the 
cerebellum in humans. Ann Neurol 1995;37:703–13. 
 23 
 
[55] Giuffrida JP, Riley DE, Maddux BN, Heldmann D a. Clinically deployable kinesia 
technology for automated tremor assessment. Mov Disord 2009;24:723–30. 
[56] Heldman D a., Giuffrida JP, Chen R, Payne M, Mazzella F, Duker AP, et al. The modified 
bradykinesia rating scale for Parkinson’s disease: Reliability and comparison with 
kinematic measures. Mov Disord 2011;26:1859–63. 
[57] Heldman D a., Espay AJ, LeWitt P a., Giuffrida JP. Clinician versus machine: Reliability 
and responsiveness of motor endpoints in Parkinson’s disease. Park Relat Disord 
2014;20:590–5. 
[58] Ilg W, Giese M a, Gizewski ER, Schoch B, Timmann D. The influence of focal cerebellar 
lesions on the control and adaptation of gait. Brain 2008;131:2913–27. 
[59] Manto M, Bower JM, Conforto AB, Delgado-García JM, Da Guarda SNF, Gerwig M, et 
al. Consensus paper: Roles of the cerebellum in motor control-the diversity of ideas on 
cerebellar involvement in movement. Cerebellum 2012;11:457–87. 
[60] Horak FB. Clinical assessment of balance disorders. Gait Posture 1997;6:76–84. 
[61] Benninger DH, Iseki K, Kranick S, Luckenbaugh D a., Houdayer E, Hallett M. Controlled 
Study of 50-Hz Repetitive Transcranial Magnetic Stimulation for the Treatment of 
Parkinson Disease. Neurorehabil Neural Repair 2012;26:1096–105. 
[62] Von Papen M, Fisse M, Sarfeld AS, Fink GR, Nowak D a. The effects of 1 Hz rTMS 
preconditioned by tDCS on gait kinematics in Parkinson’s disease. J Neural Transm 
2014;121:743–54. 
[63] Bohnen NI, Müller ML, Dauer WT, Albin RL. Parkinson’s disease: what role do 
pedunculopontine cholinergic neurons play? Future Neurol 2014;9:5–8. 
[64] Tard C, Delval a., Devos D, Lopes R, Lenfant P, Dujardin K, et al. Brain metabolic 
abnormalities during gait with freezing in Parkinson’s disease. Neuroscience 
2015;307:281–301. 
[65] Brugger F, Abela E, Hagele-Link S, Bohlhalter S, Galovic M, Kagi G. Do executive 
dysfunction and freezing of gait in Parkinson’s disease share the same neuroanatomical 
correlates? J Neurol Sci 2015;356:184–7. 
[66] Göttlich M, Münte TF, Heldmann M, Kasten M, Hagenah J, Krämer UM. Altered Resting 
State Brain Networks in Parkinson’s Disease. PLoS One 2013;8. 
[67] Helmich RC, Derikx LC, Bakker M, Bloem BR, Toni I. Spatial Remapping of Cortico-
striatal Connectivity in Parkinson ’ s Disease. Cereb Cortex 2010;20. 
 24 
 
[68] Rubino A, Assogna F, Piras F, Di Battista ME, Imperiale F, Chiapponi C, et al. Does a 
volume reduction of the parietal lobe contribute to freezing of gait in Parkinson’s disease? 
Park Relat Disord 2014;20:1101–3. 
[69] Chan HF, Kukkle PL, Merello M, Lim SY, Poon YY, Moro E. Amantadine improves gait 
in PD patients with STN stimulation. Park Relat Disord 2013;19:316–9. 
[70] Théoret H, Haque J, Pascual-Leone A. Increased variability of paced finger tapping 
accuracy following repetitive magnetic stimulation of the cerebellum in humans. Neurosci 
Lett 2001;306:29–32. 
[71] Miall RC, Christensen LOD. The effect of rTMS over the cerebellum in normal human 
volunteers on peg-board movement performance. Neurosci Lett 2004;371:185–9.  
 
  
 25 
 
Chapter 2: Cerebellar involvement in Parkinson’s disease resting tremor 
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Abstract 
 
There exists a lack of consensus regarding how cerebellar over-activity might influence 
tremor in Parkinson’s disease (PD). Specifically, it is unclear whether resting or postural tremor 
are differentially affected by cerebellar dysfunction. It is important to note that previous studies 
have only evaluated the influence of inhibitory stimulation on the lateral cerebellum, and have 
not considered the medial cerebellum. Thus, the aim of the current study was to compare the 
effects of a low-frequency rTMS protocol applied to the medial versus lateral cerebellum to 
localize the effects of cerebellar over-activity. Fifty PD participants were randomly assigned to 
receive stimulation over the medial cerebellum (n=20), lateral cerebellum (n=20) or sham 
stimulation (n=10). 900 pulses were delivered at 1Hz at 120% resting motor threshold of the first 
dorsal interosseous muscle. Tremor was assessed quantitatively (before and after stimulation) 
using the Kinesia Homeview system which utilizes a wireless finger accelerometer to record 
tremor. The main finding was that resting tremor frequency was reduced in tremor-dominant 
individuals, regardless of whether stimulation was applied over the medial (p=0.024) or lateral 
(p=0.033) cerebellum, but not in the sham group. Given that the cerebellum is overactive in PD, 
the improvements in resting tremor following an inhibitory stimulation protocol suggest that 
over-activity in cerebellar nuclei may be involved in the generation of resting tremor in PD. 
Low-frequency rTMS over the medial or lateral cerebellum provides promise of an alternative 
treatment for tremor in PD, a symptom that is poorly responsive to dopaminergic replacement.   
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Introduction  
 
Parkinson’s disease (PD) symptoms have generally been associated with dysfunction of 
the basal ganglia, and specifically, with the loss of dopaminergic producing neurons in the 
substantia nigra [1]. However, since increased activation levels of the cerebellum are also found 
in individuals with PD, it has been suggested that not all PD motor symptoms are due entirely to 
basal ganglia dysfunction [28,30,32]. Given the anatomical connections between the cerebellum 
and the basal ganglia, it has been suggested that increased cerebellar activity may also contribute 
to the pathophysiology of PD symptoms[28–30]. It is possible that increased excitatory output 
from the subthalamic nucleus in PD may be propagated to the cerebellum, via the pontine nuclei, 
and account for hyperactivity in cerebellar nuclei [30]. Understanding the effects of increased 
cerebellar nuclei activity in PD may be the key to gaining insight into some of the mechanisms 
underlying symptoms that are non-responsive or variably responsive to dopaminergic 
replacement.  
Symptoms of bradykinesia and rigidity in PD demonstrate a stronger link with 
dysfunction of the basal ganglia and dopaminergic loss, while tremor seems to be less implicated 
with dopamine [27,28,34]. Given that tremor symptoms are generally less responsive to 
dopaminergic treatment, this might suggest that the pathophysiology of this symptom could be 
more related to over-activity in the cerebellum. Increased functional connectivity between the 
basal ganglia and cerebellum has been found in individuals with PD who experience tremor [33]; 
it has been suggested that while the basal ganglia may generate tremor, it is over-activity of the 
cerebellum that drives the tremor pattern [34].  In order to help understand the role of cerebellar 
over-activity in tremor, methods to suppress or reduce activity in the cerebellar nuclei provide a 
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means to assess how PD symptoms might change under a temporary state of cerebellar 
depression. 
The assessment of changes in tremor following repetitive transcranial magnetic 
stimulation (rTMS) protocols designed to transiently inhibit activity in the cerebellar nuclei are 
methods utilized in research to help determine whether it might be over-activity in the 
cerebellum contributing to this symptom. Other forms of TMS protocols have also been used to 
understand the involvement of the cerebellum in PD tremor. For example, tremor reset is a 
measure used to confirm the contribution of a brain area to either the generation or transmission 
of tremor. If the cortical target of TMS is involved in the pathophysiology of tremor, the effect of 
the stimulation interrupts the ongoing tremor drive and causes a tremor reset. A paired-pulse 
TMS protocol by Ni et al. (2010) demonstrated the involvement of the cerebellum in PD tremor 
by showing a reset of postural tremor following single-pulse cerebellar and primary motor cortex 
(M1) stimulation. It is important to note, however, that despite tremor reset, there was no change 
in tremor frequency following stimulation, and the effects were found only for postural, but not 
resting tremor after cerebellar stimulation [33]. In contrast, a study by Bologna et al. (2015) 
demonstrated no changes in resting tremor severity following continuous theta burst stimulation 
(cTBS) over the lateral cerebellum. This group suggested no involvement of the cerebello-
thalamo-cortical loop in the generation of PD tremor [47]. Another study by Minks et al. (2011), 
which utilized one single session of low frequency (1Hz) rTMS over the right lateral cerebellum 
found significant improvement in bradykinesia of gross motor skills of both hands following 
stimulation. Although there was a benefit to gross motor skills, fine motor skills worsened and 
was only seen on the hand ipsilateral to stimulation [48]. A trial with greater clinical benefits 
using rTMS was that of Koch et al. (2009) which employed a two-week treatment of bilateral 
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cerebellum using cTBS. This study resulted in reduced levodopa-induced dyskinesias (LIDs) for 
a period up to four weeks following the stimulation protocol [49]. These studies demonstrate a 
link between the modulation of cerebellar activity and some level of change in motor symptoms, 
suggesting the cerebellum may play a role in the pathophysiology of PD motor symptoms. The 
previous studies also demonstrate how inhibitory TMS protocols may be a useful tool for 
developing a better understanding of how the cerebellum might contribute to PD symptoms.  
It is important to note that these previous studies applied stimulation targeted only to the 
lateral cerebellum, whereupon the cerebellar output nucleus (dentate) relays in the thalamus and 
basal ganglia. Additionally, these previous studies may not have had a pure sample of tremor 
dominant PD participants, which is important because not all individuals with PD present with 
tremor. Hence, this may have potentially lead to variable tremor results following cerebellar 
modulation. It may be beneficial to include a non-tremor dominant PD control group to ensure 
tremor results are definitive. Therefore, the aim of the current study was to use a low frequency 
rTMS protocol to transiently inhibit neural activity in the cerebellum of individuals with PD to 
further understand how over-activity in the cerebellum may contribute to tremor. Further, to 
localize the effects of over-activity in specific cerebellar nuclei, a direct comparison controlled 
by sham stimulation was done between the effects of stimuli applied over the medial versus 
lateral cerebellum. The assessment of changes in this less dopaminergic responsive PD motor 
symptom has the potential to uncover new knowledge about cerebellar pathophysiology in PD 
tremor. Further understanding of the involvement of cerebellar activity in PD has the potential to 
guide the development of treatments targeted to those symptoms which are less responsive to 
dopaminergic replacement therapy, such as tremor. 
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Methods 
 
Participants 
 
Fifty individuals diagnosed with idiopathic PD who met inclusion criterion were 
recruited for participation from the Movement Disorders Research & Rehabilitation Centre 
database (Wilfrid Laurier University, Waterloo, Ontario, Canada). For participant demographics, 
see Table 1. For safety, individuals who had received deep brain stimulation, implanted 
aneurysm clips or cochlear implants were excluded from participation. Previous history of 
seizures or the prescription of medications which lower the seizure threshold were also criterion 
for exclusion. Given the requirement to limit movements of the head and neck during 
stimulation, individuals with severe dyskinesia in the neck muscles were also excluded. 
Participants were blinded and randomized into three groups: Medial (n=20), Lateral (n=20) or 
Sham (n=10). This study was approved by the research ethics board at Wilfrid Laurier 
University, with all participants providing informed consent. 
Stimulation Protocol 
 
Stimulation was delivered using a Magstim Rapid2 with 70mm double air film coil 
(Magstim, UK) guided by TMS Manager navigation (Northern Digital Inc., Waterloo, Ontario). 
Stimulation intensity was based upon the resting motor threshold (RMT) of the right first dorsal 
interosseous (FDI) muscle. The measurement of resting electromyography (EMG) activity of the 
hand in individuals with PD is difficult due to the constant muscle activity from the generation of 
tremor, however, FDI has been shown in previous work to be capable of maintaining a level of 
muscle relaxation comparable to healthy individuals [33].  
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The motor hot spot for the FDI muscle was found in the primary motor cortex (M1) by 
systematically modifying coil placement and orientation until a consistently isolated FDI 
contraction was found. RMT was determined by decreasing stimulator output in 1% intervals and 
defined as the lowest stimulus intensity which produced a motor evoked potential of 50-100µV 
in amplitude in at least 5 out of 10 consecutive responses with the hand relaxed [15,29,50]. RMT 
served to standardize the stimulus intensity relative to individual motor thresholds and varying 
levels of cortical excitability across participants.  
The stimulation protocol consisted of one single session, where 900 pulses at 1Hz were 
applied at 120% RMT. Previous studies have shown that 900 pulses is sufficient for cerebellar 
suppression [50,51]. In the absence of individual magnetic resonance images (MRI) to determine 
exact structure depth, the higher stimulation intensity was used to account for the increased 
distance between the coil and the cerebellum in comparison to the motor cortex [52,53]. The 
stimulation target was either the cerebellar vermis (medial group) or lateral cerebellum (lateral 
group). The vermis is located directly beneath the inion, and was located through surface 
palpation. The lateral cerebellum, or dentate nucleus, is located three centimetres lateral and one 
centimetre inferior to the vermis [54]. Lateral cerebellar stimulation was applied to the side of 
the participant that was most affected by PD symptoms. Side affected was determined by self-
report and confirmed by clinician assessment. All stimulation (both real and sham) was applied 
while participants were seated with their face resting on a padded surface, creating both a 
comfortable position for the participants, while at the same time minimizing head and neck 
movement. Sham stimulation was employed by angling the coil at 90 degrees to the participants’ 
scalp, following the same protocol as real stimulation. All stimulation (real and sham) was 
delivered while participants were in their ON medication state.  
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Outcome Measures 
 
The Unified Parkinson’s Disease Rating Scale motor sub-section (UPDRS-III) scores for 
each participant were assessed by a blinded movement disorders specialist before beginning the 
study. Participants were then assessed for baseline tremor severity before receiving either real or 
sham stimulation, and then assessed again immediately following the stimulation.  
Quantitative measures of tremor were assessed for each hand using the Kinesia 
Homeview tablet, which is equipped with a wireless motion sensor that is placed on the index 
finger. The motion sensor consists of 3 accelerometers and 3 gyroscopes which are able to 
capture motion of the hands in the x,y and z planes at 128Hz. The output is then run through a 
previously validated algorithm by the Kinesia software and calculates a tremor severity score 
which ranges from 0 to 4 at a resolution of 0.1 [55–57]. This score, which has been demonstrated 
to be highly correlated with clinician ratings, is based upon kinematic measures including peak 
power, frequency of peak power and root mean square of angular velocity [55–57]. While in the 
seated position, tremor was recorded for 15 seconds separately for each hand. Participants were 
instructed to relax the hands between the legs to assess resting tremor, during which time the 
stroop task was presented to distract participants from tremor activity. Participants were 
instructed to raise both arms directly in front to shoulder height to assess postural tremor. .  
Analysis 
 
Given that the presence of motor symptoms is heavily dependent on PD subtypes, a two-
way repeated measures ANOVA with two independent factors was run to account for either the 
presence or absence of tremor in participants. Participants who had high scores on the upper limb 
section of the UPDRS-III assessment compared to the lower limb section were classified and 
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tremor dominant (TD). Likewise, participants with higher scores in the lower limb compare to 
the upper limb section were classified as postural instability and gait dominant (PIGD). This 
analysis compared stimulation (Lateral vs Medial vs Sham) and PD Subtype (Tremor Dominant 
(TD) vs Postural Instability Gait Impaired Dominant (PIGD)) and one within factor (Pre-
assessment vs Post-assessment). This analysis was run for both hands combined, as well as the 
most affected hand by PD symptoms separately, to account for the ipsilateral effects expected 
from lateral stimulation of the cerebellum.  
With the expectation that tremor symptoms would only improve in tremor-dominant 
participants, a second mixed repeated measures ANOVA comparing the effects of stimulation 
(Lateral vs Medial vs Sham) from pre-assessment to post-assessment using only TD patients 
(except for the Sham group) was run. Any significant findings were further examined with 
Tukey’s HSD post hoc procedure.  
 
Results 
 
Tremor outcome data was not included from three participants, therefore statistical 
analysis was run on 19 participants who received medial stimulation, 20 participants who 
received lateral stimulation and 8 participants who received sham stimulation (total 47 
participants). Data was found to be normally distributed. 
The two-way repeated measures ANOVA did not produce any statistically significant 
interactions, however the analysis did demonstrate a clear advantage for taking into account the 
presence of tremor as an independent factor. Graphical representation of the results of resting 
tremor showed no change in the PIGD group, meanwhile there appears to be a trend towards 
improvement in both rest and postural tremor in the TD participants regardless of whether the 
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medial or lateral stimulation was applied. This result was consistent for analyses looking at the 
results from both hands combined (See Figures 1 & 2), as well as for the hand most affected by 
PD tremor (See Figure 3). 
A mixed repeated measures ANOVA, including only TD participants, showed a near-
significant time x stimulation interaction (F(2,25)=2.89, p=0.07), demonstrating a decrease in 
tremor frequency at post-assessment for both the medial and lateral stimulation groups (Figure 
3). Post hoc analysis revealed the medial stimulation group to have improved tremor by 29.1% 
(p=0.024) and lateral stimulation to have improved by 37.5% (p=.033). Importantly, there was 
no change in the sham stimulation group, demonstrating this effect could not be attributed to 
placebo effects. Given there were only 5 participants in the sham group who were classified as 
tremor dominant, this group was not divided based on PD subtype to preserve statistical power. 
This would not have influenced the results since the previous ANOVA (using tremor dominance 
as an independent factor) did not indicate any placebo effect of sham stimulation on TD or PIGD 
participants.  
Discussion 
 
The aim of the current study was to use a low frequency rTMS protocol to transiently 
inhibit activity in the cerebellum of individuals with PD to gain an understanding of how 
localized over-activity in the cerebellum may contribute to tremor symptoms. The effects of 
stimulation were assessed based upon changes in tremor symptoms, where a change or 
improvement following inhibitory stimulation might suggest the involvement of cerebellar over-
activity in the generation of tremor.  
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To date, this is the first cerebellar rTMS protocol which indicated improvements 
specifically in resting tremor in individuals with PD. Our results suggest that the severity of 
resting tremor was reduced in individuals regardless of whether stimulation was applied over the 
medial or lateral cerebellum (although it appears that the lateral cerebellum was the more 
effective target). This effect was specific to individuals with PD who were tremor-dominant, 
suggesting involvement of the cerebellum in the generation of resting tremor. This is in contrast 
to previous work which utilized continuous theta burst stimulation and found no change to 
resting tremor frequency, concluding the cerebello-thalamo-cortical circuit to have no 
involvement at all in the generation of resting tremor [47].  Another study which utilized a 
paired-pulse stimulation paradigm, suggested the isolated involvement of the cerebellum in 
postural tremor only, and not resting tremor [33]. This might suggest the generation of resting 
and postural tremor to be from different pathways. Findings from the current study, however, 
provide evidence which supports the theory that hyperactivity in the cerebellum contributes to 
resting tremor in PD. Key differences in the current study such as an objective measure of 
tremor, the comparison between medial and lateral stimulation, and analysis by tremor-
dominance, may have enabled these findings. 
Given that a low frequency, inhibitory stimulation was applied, the trend towards 
improvement in resting tremor may be attributed to the potential normalization of the activation 
level in the cerebellar circuitry. The cerebello-thalamo-cortical pathway might allow 
transmission of cerebellar excitability changes to the thalamus, basal ganglia and M1. Thus, there 
are two pathways in which the cerebellum may interrupt the ongoing tremor drive: i) cerebellum-
thalamus-primary motor cortex, or ii) cerebellum-thalamus-basal ganglia loop-primary motor 
cortex. Interestingly, inhibitory stimulation applied over the medial or lateral cerebellum both 
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benefit resting tremor by supressing the output from either the dentate or fastigial nucleus in PD 
(though results suggest lateral stimulation to be slightly more effective). It is important to note 
the inhibitory effects of stimulation may not have reached the deep cerebellar nuclei, and thus 
tremor improvements could alternatively be the result of modulation of cerebellar cortex activity. 
Given the net inhibitory output of the Purkinje cells in the cerebellum, modulation at the level of 
the cerebellar cortex may have indirectly affected activity of the deep cerebellar nuclei. 
Alternatively, the spread of TMS current could have stimulated the interpositus nuclei (which 
lies between the fastigial and dentate nuclei) and thus the effects could have been the result of 
modulation of spinocerebellar tracts. However, since differential effects between stimulation 
applied to the medial versus lateral cerebellum were found (where the lateral stimulation target 
appeared to be more effective) the spread of TMS current can be ruled out. Only if the effects 
were found to be identical following stimulation of either cerebellar target could the spread of 
TMS current be thought to have contributed to tremor modulation.  Knowing that tremor has 
previously been shown to be unrelated to levels of striatal dopamine depletion [34], this study 
supports the theory that the pathophysiology of tremor-dominant PD may be less associated with 
dysfunction of the basal ganglia and more related to over-activity in the cerebello-thalamo-
cortical circuit [27].  
To build upon the current evidence, an important extension of this study would be to 
recruit a larger sample, consisting of only tremor-dominant PD participants. This would provide 
adequate power to assess exactly how significant the improvement might be in this PD sub-
group. Further, it is important to understand what other effects the stimulation may have had on 
the PIGD sub-group. Since there was no improvements in tremor expected in the PIGD sub-
group, an assessment of how the stimulation may effect gait and balance symptoms should be 
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considered. The assessment of changes in gait and balance outcome measures would also be 
important for the TD sub-group, since the cerebellum is an important subcortical structure 
implicated in the control of gait and balance. Understanding of the more global effect this 
stimulation may have on less-dopaminergic responsive PD symptoms, encompassing tremor, gait 
and balance would help to determine the therapeutic potential of low frequency inhibitory 
stimulation.  
Overall, this study suggests the involvement of the medial and lateral cerebellum in the 
generation of resting tremor in PD. These single sessions of inhibitory stimulation over either the 
medial or lateral cerebellum provide evidence to suggest that long-term application of the 
inhibitory protocol, consisting of multiple rTMS sessions, could potentially produce longer 
lasting benefits. Understanding the mechanisms underlying the cerebellar pathophysiology in PD 
has the potential for developing new treatments for symptoms which are less responsive to 
dopaminergic replacement.  
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Tables & Figures: 
 Medial Lateral Sham 
N 20 (4F, 16M) 20 (6F, 14M) 10 (3F, 7M) 
Age (years) 69.4 66.8 71.1 
UPDRS-III 22.7 23.1 19.5 
Table 1: Participant demographics; no significant differences. 
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Table 2: Participant demographics following stratification by tremor dominance or gait 
dominance. 
 
  Medial, 
Tremor 
 Medial, 
PIGD 
Lateral, 
Tremor 
 Lateral, 
PIGD 
 Sham 
N 12 (3F, 9M) 8 (1F, 7M) 8 (3F, 5M) 12 (3F, 9M) 10 (3F, 7M) 
Age 
(years) 
71.4 (6.9) 66.7 (10.8) 59.1 (12.8)* 71.3 (9.0) 71.1 (8.7) 
UPDRS-
III 
24.8 (6.7) 19.5 (9.9) 25.4 (12.5) 21.5 (10.3) 19.5 (8.0) 
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Figure 1: Resting tremor measures for both sides combined. Standard error of each measure 
represented by vertical bars. 
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Figure 2: Postural tremor measures for both sides combined. Standard error of each measure 
represented by vertical bars. 
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Figure 3: Resting tremor measures for the side most affected by PD demonstrate near- 
significant group x time interaction (F(2,25)=2.89, p=0.074). Standard error of each measure 
represented by vertical bars. 
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Chapter 3: Does cerebellar over-activity contribute to gait and balance deficits in PD? 
Submitted to: Gait & Posture 
Abstract 
 
Parkinson’s disease (PD) symptoms which respond poorly to dopaminergic replacement, 
such as gait and balance deficits, point to an alternative pathology to dopaminergic dysfunction 
within the basal ganglia. For example, decreased cholinergic innervation of the 
pedunculopontine nucleus (PPN) has been related to poor balance control in PD. A second 
possibility may be that over-activity of the cerebellum contributes to balance problems, since 
other hyperkinetic motor symptoms have been linked to cerebellar dysfunction. The cerebellum 
and PPN both relay sensory information to the thalamus, however it is unclear how cerebellar 
over-activity might be affecting gait and balance deficits. Thus, the aim of the current study was 
to assess how cerebellar over-activity may be affecting gait and balance deficits in PD by 
inhibiting cerebellar activity using repetitive transcranial magnetic stimulation (rTMS). Fifty PD 
participants were randomized to receive stimulation over the medial (n=20) or lateral cerebellum 
(n=20) or sham stimulation (n=10). 900 pulses at 1Hz were delivered at an intensity of 120% 
resting motor threshold determined from the first dorsal interosseous muscle representation in the 
primary motor cortex. Balance was measured with objective, computerized protocols: modified 
clinical test of sensory integration and balance (m-CTSIB) and postural stability testing (PST). 
Spatiotemporal gait was measured quantitatively during self-paced walking. All assessments 
were performed before and after real or sham stimulation. Inhibition of the cerebellar nuclei did 
not result in modulation of gait and balance outcome measures. Hence, dysfunction of the 
cerebellum may not be a contributing factor to gait and balance deficits in PD. 
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Introduction  
 
It is well known that motor symptoms in Parkinson’s disease (PD) are related to 
dopaminergic dysfunction. However, gait and balance deficits have been shown to be poorly 
responsive to dopaminergic replacement, suggesting these deficits may have a pathology 
alternative to dopaminergic dysfunction. Over-activity of the cerebellum has been identified in 
individuals with PD [28–30,32], however the over-activity has not been localized to a specific 
area of the cerebellum. Given that the cerebellum is an important subcortical structure to the 
control of gait and balance, one obvious possibility may be that dysfunction in the cerebellum 
contributes to these symptoms. The dentate nucleus is the main output of the lateral cerebellum, 
and is thought to be responsible for using sensory information to control limb movements, while 
the fastigial nucleus is the main output of the medial cerebellum and is thought to control muscle 
tone and upright stance [58,59].  However, it is not understood how over-activity of the 
cerebellum might affect gait and balance deficits in PD. Thus, it would be advantageous to 
modulate the over-activity in the cerebellar nuclei and evaluate how this might influence gait and 
balance deficits.  
Low frequency repetitive transcranial magnetic stimulation (rTMS) is one method which 
can be used to inhibit synaptic activity within the cerebellum. Temporary inhibition in the 
current study would enable the assessment of how gait and balance symptoms might be affected 
in the absence of altered input from cerebellar nuclei. A direct comparison between the effects of 
inhibitory stimuli applied over the medial (fastigial nucleus) versus the lateral cerebellum 
(dentate nucleus) is essential to help disentangle how the cerebellar nuclei might be differentially 
affecting gait and balance deficits. Functionally, the lateral cerebellum is primarily associated 
with limb movements and gait, while the medial cerebellum is associated with upright stance 
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[58,59]. From an anatomical perspective, these stimulation targets provide the opportunity to 
modulate two separate output pathways; while output from both nuclei relays first in the 
thalamus, the key difference is output from the dentate nucleus (but not the fastigial nucleus) is 
additionally relayed in the basal ganglia before reaching the motor cortex. Given the close 
proximity of the stimulation areas, an advantage of comparing both targets from a technical 
perspective is the additional level of control to account for the potential spread of TMS current. 
Hence, the aim of the current study was to evaluate how over-activity in the medial and lateral 
cerebellum might be influencing gait and balance deficits in PD.  
It is hypothesized that temporary inhibition of the medial cerebellum will result in 
improved static balance, characterized by decreased postural sway during assessments. In 
addition, it is hypothesized that the non-dopaminergic responsive gait parameters, such as single 
and double limb support time, will improve following lateral cerebellar stimulation. It is 
anticipated that stimulation applied to the medial cerebellum will demonstrate greater 
improvement of symptoms since the output from the fastigial nucleus does not relay in the 
dysfunctional basal ganglia. Understanding the influence of cerebellar over-activity in PD has 
the potential to uncover new knowledge regarding mechanisms underlying symptoms which are 
poorly responsive to dopaminergic replacement, such as gait and balance deficits. 
Methods 
 
Participants 
 
Fifty individuals diagnosed with idiopathic PD were recruited for participation from the 
Movement Disorders Research & Rehabilitation Centre database (Wilfrid Laurier University, 
Waterloo, Ontario, Canada). For participant demographics, see Table 1. For safety, individuals 
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who had received deep brain stimulation, implanted aneurysm clips or cochlear implants were 
excluded from participation. Previous history of seizures or the prescription of medications 
which lower the seizure threshold were also criterion for exclusion. Given the nature of the 
assessments, participants were required to be able to walk five metres, in addition to standing for 
five minutes unassisted. Eligible participants were blinded and randomized into three stimulation 
groups: Medial target (n=20), Lateral target (n=20) or Sham (n=10). This study was approved by 
the research ethics board at Wilfrid Laurier University, with all participants providing informed 
consent. 
Stimulation Protocol 
 
Stimulation was delivered using a Magstim Rapid2 with 70mm double air film coil 
(Magstim, UK) guided by TMS Manager navigation (Northern Digital Inc., Waterloo, Ontario). 
Stimulation intensity was based upon the resting motor threshold (RMT) of the right first dorsal 
interosseous (FDI) muscle hot spot in the left primary motor cortex (M1), in accordance with Ni 
et al [33]. RMT was determined by decreasing stimulator output in 1% intervals and defined as  
the lowest stimulus intensity which produced a motor evoked potential of 50-100µV in 
amplitude in at least 5 out of 10 consecutive responses with the hand relaxed [15,29,50]. RMT 
allows standardization of stimulus intensity to be reflective of inter-individual variability in 
motor thresholds and cortical excitability across participants.  
The stimulation protocol consisted of one single session, where 900 pulses at 1Hz were 
applied at 120% RMT. Previous studies have shown 900 pulses to be sufficient for cerebellar 
suppression [50,51]. The higher stimulation intensity was used to account for the increased 
distance between the coil and the cerebellum in comparison to the motor cortex [52]. The 
stimulation target was either the cerebellar vermis (medial group) or lateral cerebellum (lateral 
 52 
 
group). The vermis is located directly beneath the inion, and was located through surface 
palpation. The lateral cerebellum, or dentate nucleus, is located three centimetres lateral and one 
centimetre inferior to the vermis. Lateral cerebellar stimulation was applied to the side of the 
participant that was most affected by PD symptoms. Side affected was determined by self-report 
and confirmed by clinician assessment. All stimulation (both real and sham) was applied while 
participants were seated with their face resting on a padded surface, creating both a comfortable 
position for the participants, while at the same time minimizing head and neck movement. Sham 
stimulation was employed by angling the coil at 90 degrees to the participants’ scalp, following 
the same protocol as real stimulation. All stimulation (real and sham) was delivered while 
participants were in their ON medication state.  
Outcome Measures 
 
The Unified Parkinson’s Disease Rating Scale motor sub-section (UPDRS-III) scores for 
each participant were assessed by a blinded movement disorders specialist prior to any 
assessments or stimulation. Participants next performed baseline gait and balance assessments in 
a randomized order. Participants then received either sham or real rTMS (medial or lateral 
cerebellar target) in accordance with group randomization. Immediately following stimulation, 
participants were again assessed on gait and balance outcome measures, with the total visit 
taking 1.5 hours. Spatiotemporal gait parameters were measured and assessed using a Zeno 
Walkway System (ProtoKinetics, Havertown, PA, USA) with ProtoKinetics Movement Analysis 
Software (PKMAS) version 507c7c. Participants were instructed to begin walking on the 
experimenters command, starting one metre back from the edge of the carpet to account for 
acceleration, and to walk at least one meter beyond the end of the carpet to account for 
deceleration. Alongside a spotter, participants completed 5 walking trials before stimulation and 
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again after receiving stimulation. Gait outcome measures included: step length, step time, step 
width, swing time, cadence, velocity, stance time and percentage of time spent in single limb and 
double limb support. These measures included gait parameters known to be responsive and/or 
non-responsive to dopaminergic treatment, with the intention to disentangle which specific 
parameters might be modulated with cerebellar stimulation.  
Balance control and postural stability were measured using the Biodex Balance System 
SD (Biodex Medical Systems Inc., Shirley, New York), in accordance with the postural stability 
testing (PST) and the modified clinical test of sensory integration and balance (m-CTSIB) 
protocols. Given that proprioceptive and sensory integration deficits are known to affect balance 
control in PD [39–43], it is important to assess balance under varying sensory conditions. The 
PST protocol averages centre of pressure deviations from three quiet balance trials, each lasting 
thirty seconds. The equipment provided scores, termed as stability index, which measured 
overall postural stability, in addition to scores in the medio-lateral and anterior-posterior planes. 
The m-CTSIB protocol has been validated for quantifying an individual’s sensory organization 
during the performance of balance tasks [60]. In this protocol, balance control was measured 
during twenty second trials in each of four sensory conditions: 1) eyes open firm surface, 2) eyes 
closed firm surface, 3) eyes open foam surface and 4) eyes closed foam surface. The equipment 
generates a sway score, which was produced from the variability (standard deviation) of postural 
deviations from a central reference point. For both the m-CTSIB and the PST protocols, high 
scores were indicative of poor balance control. 
Analysis:  
A mixed repeated measures ANOVA was run for each of the gait and balance outcome 
measures which compared the effects of stimulation (Medial vs Lateral vs Sham) across time 
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(pre-assessment vs post-assessment). Any significant findings were further analyzed with 
Tukey’s HSD post hoc procedure.  
Results 
 
Gait 
Data for two participants was compromised, thus analyses were done on a total of 48 
participants (20 medial, 19 lateral, 9 sham). Gait analysis revealed no significant effects of 
stimulation on any of the spatiotemporal gait parameters measured (see Table 2).  
Balance 
 
There were no significant effects of stimulation found in any of the PST outcome 
measures (see Table 3). Similarly, there were no significant effect of the stimulation on m-
CTSIB outcome measures; however, there was a main effect of vision (F(1,45)=137.79, 
p=0.000) demonstrating significantly worse balance overall in the eyes closed conditions, as well 
as a main effect of surface (F(1,45)=64.97, p=0.000) showing balance to be significantly worse 
for all participants on the foam surface. These findings were further supported by a significant 
vision x surface interaction (F(1,45)=15.92, p=0.00001), where the worst balance overall was 
found with the eyes closed on the foam surface.  
Discussion 
 
 This was the first study to target the cerebellum using low-frequency rTMS to evaluate 
the influence of cerebellar over-activity on gait and balance deficits in PD. Systematic 
evaluations of gait and balance were performed to directly compare the effects of rTMS on 
medial versus lateral cerebellum, in contrast to sham stimulation. The main finding was that 
spatiotemporal gait parameters and static balance were not affected by stimulation applied to 
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either cerebellar target. The current findings are in contrast to previous studies which found 
improved gait following various rTMS protocol which targeted the primary motor cortex (M1) in 
individuals with PD. Improvements in walking speed were found following 5 Hz rTMS [9], 0.5 
Hz rTMS [10] and 25 Hz rTMS [6], but not following single or multiple sessions of 50 Hz 
intermittent theta burst stimulation [11,61]. Given that inhibitory stimulation applied to the 
cerebellum has previously been shown to decrease M1 excitability[52], and influence gait 
parameters in healthy individuals [6,9,10,62], improvements in gait following cerebellar 
inhibition during the current study might have been expected.  However, regardless of medial or 
lateral cerebellar stimulation, spatiotemporal gait parameters and static balance were not 
affected, suggesting cerebellar over-activity may not contribute to gait and balance deficits in 
PD. 
Gait parameters such as velocity, stride length and stride time demonstrate improvements 
after dopaminergic replacement, suggesting these deficits might be primarily related to the 
dysfunctional basal ganglia. Meanwhile, other gait parameters such as step frequency and double 
limb support time have proven to be unresponsive to dopaminergic treatment [36–38], 
suggesting an additional mechanism to basal ganglia dysfunction must also be involved in gait 
deficits. Given that proprioceptive deficits have previously been well established in PD [39–43], 
alternative mechanisms to consider might involve poor sensory processing.  
One alternative mechanism is cholingeric denervation in the PPN, which has been 
demonstrated by previous research to negatively affect sensory processing, leading to gait and 
balance deficits in PD [45,63]. One way to conceptualize this idea is to think about the sensory 
inputs relaying in the thalamus; both the PPN and the cerebellum relay sensory information in 
the ventrolateral nucleus of the thalamus, however, both provide poor inputs in PD. The PPN 
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input may be negatively affected by decreased cholinergic innervation [45,63], and the cerebellar 
input may be negatively affected by over-activity in the cerebellar nuclei. Therefore, there could 
be two sources of “broken” input for sensory integration which are relaying in the thalamus in 
PD; the combination of these two inputs may compound to result in poor sensory integration, and 
thus, gait and balance deficits. If this was true, then inhibition of the cerebellar output (via 
rTMS) may have reduced the load on the thalamus by reducing the number of “broken” inputs to 
only one input, that being the input coming from the denervated PPN. Importantly, there was no 
change or improvement in gait or balance symptoms following transient inhibition of the 
cerebellum, suggesting that PPN cholinergic denervation, and the “broken” signals which result, 
may have prevailed. This theory would suggest that cerebellar over-activity must not compound 
the effects of PPN denervation and thus, further impair sensory integration at the level of the 
thalamus. Hence, cholinergic denervation as opposed to over-activity in the cerebellum might be 
one contributor to gait and balance deficits in PD. 
The influence of the dysfunctional basal ganglia on gait and balance symptoms cannot be 
ignored. Comparing the effects of stimulation targeted to the medial versus lateral cerebellum 
would enable indirect assessment of basal ganglia involvement (since medial cerebellar output 
output does not relay in the basal ganglia). It should be noted the current experimental paradigm 
cannot directly assess basal ganglia involvement, however, this consideration might further 
support the idea of PPN involvement in gait and balance deficits. The theoretically “normalized” 
output from the cerebellum must first relay in the thalamus, whereupon the output from the 
cholinergic dennervated PPN could simultaneously “damage” this cerebellar output. Thus, 
“broken” output from the lateral cerebellum (after relaying in the thalamus) would reach the 
dysfunctional basal ganglia and likely be further impaired.  Since dysfunction of the basal 
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ganglia has also been related to abnormal sensory processing in PD, it might then be suggested 
that both the basal ganglia and the PPN influence gait and balance deficits.   
Within the sensory system, another alternative mechanism that may be influencing gait 
and balance deficits in PD is dysfunction of the parietal cortex. Individuals with PD who have 
severe gait deficits demonstrate increased activity in the parietal cortex [64], an area which is 
important for sensory processing. This increased activation of the parietal areas during gait has 
been suggested to reflect abnormal sensory processing. This has been suggested to lead to gait 
deficits in PD [64–66], as a result of the inability of individuals to process relative sensory 
information from the environment. Striatal dopamine degeneration has also been linked to a shift 
in coupling of the inferior parietal cortex from the posterior putamen to the anterior putamen 
[67], which suggests these parietal cortex changes to be PD-specific. A reduction in gray matter 
volume, and selective parietal cortex atrophy has also been found in PD [68]. Given the parietal 
cortex is an important structure in sensory processing during gait and balance, it might be 
suggested that dysfunction of this area, as opposed to cerebellar over-activity, may also be 
contributing to these deficits in PD.  
The findings from the current study do not support the involvement of the cerebellum in 
gait and balance deficits in PD, however it does support previous research which suggests that 
cholinergic denervation in the PPN may be responsible for poor sensory integration at the level 
of the thalamus, and thus, poor balance control. These findings also support the notion that rTMS 
protocols targeting the primary motor cortex, as opposed to the cerebellum, may provide greater 
clinical benefit. Further research aimed at understanding the mechanisms by which PPN 
denervation is affecting sensory integration at the level of the thalamus may have the potential to 
lead to novel treatments for gait and balance deficits in PD.   
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Tables & Figures: 
 Medial Lateral Sham 
N 20 (4F, 16M) 20 (6F, 14M) 10 (3F, 7M) 
Age (years) 69.4 (9.1) 66.8 (12.1) 71.1 (8.7) 
UPDRS-III 22.7 (8.6) 23.1 (11.4) 19.5 (8.0) 
Table 1: Participant demographics; no significant differences.  
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Gait Parameter Time Group 
Medial Lateral Sham 
Step Length (cm) Pre 60.4 (10.7) 63.8 (16.1) 59.5 (15.6) 
Post 60.1 (9.3) 64.9 (15.7) 59.9 (15.6) 
Step Length Variability (cv) Pre 5.7 (2.9) 8.2 (8.9) 6.9 (5.1) 
Post 5.7 (2.8) 6.2 (4.4) 6.6 (4.5) 
Step Time (s) Pre 0.54 (0.05) 0.57 (0.07) 0.56 (0.04) 
Post 0.53 (0.05) 0.55 (0.06) 0.55 (0.05) 
Step Time Variability (cv) Pre 4.42 (1.2) 5.78 (5.5) 4.61 (2.0) 
Post 4.47 (1.27) 4.61 (2.1) 4.68 (2.1) 
Stance Time (s) Pre 0.73 (0.08) 0.76 (0.1) 0.74 (0.09) 
Post 0.71 (0.07) 0.72 (0.09) 0.74 (0.09) 
Stance Percent Time Pre 66.2 (3.3) 65.3 (3.7) 65.5 (3.0) 
Post 66.3 (2.9) 64.8 (2.9) 65.6 (3.4) 
Swing Time (s) Pre 0.37 (0.04) 0.39 (0.04) 0.39 (0.03) 
Post 0.36 (0.04) 0.39 (0.05) 0.38 (0.03) 
Swing Percent Time Pre 33.8 (3.3) 34.7 (3.7) 34.5 (3.0) 
Post 33.7 (2.9) 35.2 (2.9) 34.4 (3.4) 
Single Support Time (s) Pre 0.37 (0.04) 0.39 (0.04) 0.39 (0.03) 
Post 0.36 (0.04) 0.39 (0.05) 0.38 (0.03) 
Single Support Percent Time Pre 26.9 (2.9) 27.8 (2.5) 27.7 (2.4) 
Post 33.6 (2.8) 35.1 (2.9) 34.4 (3.3) 
Total Double Support Time (s) Pre 0.35 (0.08) 0.36 (0.14) 0.35 (0.09) 
Post 0.35 (0.07) 0.33 (0.08) 0.35 (0.09) 
Double Support Percent Time  Pre 32.2 (6.5) 30.5 (7.4) 30.8 (6.1) 
Post 32.6 (5.8) 29.6 (5.9) 31.1 (6.7) 
Velocity (cm/s) Pre 111.7 (22.3) 114.0 (33.4) 107.9 (30.1 
Post 113.2 (18.9) 118.4 (29.9) 109.3 (30.1) 
Table 2: Gait Outcome Measures 
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  Medial Lateral Sham 
  
  
  
  
  
  
m-CTSIB 
Eyes Open, Firm 
Pre 0.83 (0.31) 0.92 (0.39) 0.84 (0.25) 
Post 0.86 (0.28) 1.07 (0.38) 0.94 (0.49) 
Eyes Closed, Firm 
Pre 1.78 (0.74) 1.46 (0.53) 1.04 (0.35) 
Post 1.94 (0.62) 1.29 (0.51) 1.32 (0.39) 
Eyes Open, Foam 
Pre 1.58 (0.64) 2.24 (1.22) 1.46 (0.23) 
Post 1.57 (0.66) 2.12 (1.28) 3.24 (5.66) 
Eyes Closed, Foam 
Pre 3.42 (1.1) 3.54 (0.68) 3.02 (1.19) 
Post 3.17 (0.72) 3.58 (1.13) 2.89 (0.91) 
  
  
  
  
Postural 
Stability Test 
(PST) 
Overall 
Pre 0.875 (0.65) 1.02 (0.82) 1.32 (0.40) 
Post 0.71 (0.48) 1.08 (1.73) 0.87 (0.64) 
Anteroposterior 
Pre 0.66 (0.61) 0.69 (0.56) 0.9 (0.83) 
Post 0.49 (0.28) 0.71 (0.92) 0.78 (0.59) 
Mediolateral 
Pre 0.43 (0.32) 0.56 (0.79) 0.7 (0.78) 
Post 0.4 (0.33) 0.65 (1.37) 0.26 (0.16) 
Table 3: Balance Outcome Measures 
 
  
 67 
 
Chapter 4: Grand Discussion 
 
Given that the cerebellum demonstrates over-activity in PD [28,30,32], an inhibitory 
rTMS protocol was used in the current thesis to modulate this activity and assess the effects on 
motor symptoms. Of specific interest, was the response of non-dopaminergic responsive motor 
symptoms, such as tremor, gait and balance since these have been suggested to result from 
cerebellar dysfunction. Measuring the effects of the stimulation on these specific symptoms was 
done with the intention to further understand how the cerebellum might be involved in PD. The 
most influential finding from this study was that 1Hz stimulation delivered over the cerebellum 
reduced resting tremor of the hand most-affected by PD but did not influence gait or balance 
outcome measures. The improvement in resting tremor was specific to tremor-dominant 
individuals with PD, and was demonstrated regardless of whether stimulation was applied 
medially or laterally to the cerebellum. It must be noted that no changes in the sham group were 
found for any of the symptom outcome measures indicating that any effects found were specific 
to the stimulation effects and not placebo effects. These results suggest the dentate and fastigial 
nuclei may be involved in the generation of resting tremor, but not gait and balance deficits in 
PD.  
Tremor, Gait, Balance and Cerebellar Over-activity  
 
The involvement of the cerebellum in PD tremor is not an entirely new concept. Previous 
studies have debated the influence of the cerebello-thalamo-cortical circuit on tremor, where 
some studies support the theory and other studies suggest there to be no involvement of the 
cerebellum in PD tremor. Using a paired-pulse stimulation paradigm, Ni et al. (2010) 
demonstrated the reset of only postural tremor following stimulation of the cerebellum. While no 
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change in resting tremor was found following stimulation of the cerebellum, this same group 
found a reset of both resting and postural tremor when the pulse was applied over the motor 
cortex [33]. This group concluded the cerebellum to have isolated involvement in postural, but 
not resting tremor. A separate study, using continuous theta burst stimulation, found no change 
to resting tremor frequency and concluded that the cerebellum was not involved in PD resting 
tremor[47]. The current findings are in contrast to both of these studies, and suggest that the 
cerebello-thalamo-cortical circuit may in fact be influencing resting tremor in PD.  
Increased activation of the cerebellum, motor cortex and putamen has been correlated 
with clinical tremor ratings [28], which provides the rationale as to why an inhibitory stimulation 
protocol was chosen. In the same light, the improvements in resting tremor might suggest the 
reduction of cerebellar activity to be therapeutic. It is possible that the reduction in resting tremor 
may be attributed to a temporary normalization of synaptic activity in the over-active cerebellar 
nuclei. Synaptic activity in this study would have been modulated by long term depression, 
which is characterized by a decrease in synaptic strength. The induction of long term depression 
in the cerebellum requires the activation of both parallel and climbing fibres, or direct activation 
of Purkinje neurons[19–21]. The stimulation having an effect on motor symptoms might suggest 
that long term depression may have been induced for a short period of time in the cerebellum.  
The two stimulation targets in this study were the dentate nucleus (lateral cerebellum) 
and the fastigial nucleus (medial cerebellum). The lateral cerebellum is primarily associated with 
upper and lower limb movements and gait, while the medial cerebellum is associated with 
regulating extensor muscle tone and maintaining upright stance [58,59]. Inhibitory stimulation 
applied to each cerebellar nuclei has the potential to modulate activity through the output 
pathways to the motor cortex (See Figure 1). Output from the dentate nucleus relays first in the 
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thalamus and is then projected to both the striatum and globus pallidus externus of the basal 
ganglia before reaching the motor cortex [28–30]. Outputs from the fastigial nucleus relay only 
in the thalamus before projecting straight to the motor cortex. Thus, there were two pathways 
that were studied with the use of rTMS in this thesis. While both pathways relay first in the 
thalamus, the key difference between output of the dentate and fastigial nuclei, is that output 
from the dentate nucleus also relays in the basal ganglia. This is important because it allows the 
assessment of the effects of inhibitory stimulation applied to the cerebellar nuclei, but also 
considers what likely ensues when this modulated output from the cerebellum reaches the 
dysfunctional basal ganglia.  
Inhibitory stimulation targeted at either the dentate or fastigial nucleus would have 
theoretically resulted in a more normalized output leaving the cerebellum to relay in the 
thalamus. However, once the output from the dentate nucleus reaches the basal ganglia (which is 
well known to be dysfunctional in PD) there are two ways in which the output may have been 
affected. First, if the dysfunctional basal ganglia were involved in tremor generation, then any 
normalization of the output coming from the dentate nucleus (due to rTMS) could be 
compromised when this output relays through the basal ganglia loops. Alternatively, if the basal 
ganglia were not involved in tremor, then the normalized output from the dentate nucleus would 
not be affected upon relay in the basal ganglia. Interestingly, stimulation applied over both the 
medial and lateral cerebellum had similar effects on resting tremor, however the improvement 
was slightly greater when stimulation was targeted to the lateral cerebellum. These results 
suggest that cerebellar over-activity is a factor contributing to resting tremor generation in PD. 
Importantly, the differential improvement between stimulation targeted to the dentate and 
fastigial nuclei suggest some level of basal ganglia involvement in resting tremor generation. The 
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improvement in resting tremor was greater following stimulation targeted at the dentate nucleus, 
whereupon the output would relay in the basal ganglia. One explanation, is the possibility that 
the normalized output from the dentate nucleus may have in some way improved the function of 
the basal ganglia. Given that the improvement in resting tremor was diminished by only 8% 
when the basal ganglia were involved, this theoretical framework does not deny involvement of 
the basal ganglia. However, the findings do support the idea that tremor in PD may be more 
related to dysfunction at the level of the cerebellum, than at the level of the basal 
ganglia[27,28,34]. 
Regardless of whether inhibitory stimulation was targeted at the dentate or fastigial 
nucleus, no improvement in gait or balance measures were found. Since the lateral cerebellum is 
thought to be responsible for integrating sensory information to control limb movements [58,59], 
it might have been expected that stimulation may have improved gait parameters. Meanwhile, 
the medial cerebellum is thought to control muscle tone and upright stance [58,59], so balance 
control improvements may have been expected following medial cerebellar stimulation. In 
contrast, these results might suggest that over-activity of the cerebellum may not be contributing 
to gait and balance deficits in PD. Importantly, the improvement in resting tremor demonstrates 
that cerebellar inhibition (both at the dentate and fastigial nuclei) was successful, meaning that 
potentially normalizing the cerebellar output must not have similar therapeutic effects on gait 
and balance deficits. One possible explanation may lie in previous research which has shown that 
individuals with PD who have severe postural instability have significantly decreased cholinergic 
innervation of the pedunculopontine nucleus (PPN)[45,63]. It has been suggested that this 
cholinergic denervation may result in poor integration and relay of sensory information at the 
thalamus, resulting in balance deficits. Importantly, cholinergic PPN neurons innervate a large 
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proportion of the thalamus, including relays for cerebellar nuclei [45,63]. Since the thalamus is 
the initial point of relay for output coming from both the dentate and fastigial nuclei, it is 
possible that the cholinergic denervation had a negative effect on the “normalized” output 
following stimulation. This might suggest that the PPN input (which is detrimental to gait and 
balance) had a greater influence on thalamus output than did the effects of normalizing the 
output of cerebellar nuclei. Thus, output contributing to poor gait and balance control was 
propagated from the thalamus to the motor cortex. Hence, it might be suggested that PPN 
cholinergic denervation and not over-activity of the cerebellum contributes to gait and balance 
deficits in PD. 
Additionally, the involvement of basal ganglia dysfunction in gait and balance 
impairments in PD must be considered [36–38,69]. Some gait parameters, such as velocity, stride 
length and stride time, demonstrate improvement following dopaminergic replacement therapy, 
indicating basal ganglia pathology [36–38]. Knowing that the dentate nucleus pathway relays in 
the basal ganglia, it might be expected that if cerebellar over-activity was involved in gait and 
balance deficits, then a greater improvement in symptoms would result following stimulation of 
the fastigial nucleus (a pathway which does not relay in the dysfunctional basal ganglia). 
Importantly, this study found no improvement following stimulation of either cerebellar target. It 
must be noted that this experimental paradigm cannot directly assess the involvement of the 
basal ganglia, however, this does further support the theory of PPN involvement. Regardless of 
the cerebellar target, the potentially normalized output following stimulation must first relay in 
the thalamus, which is simultaneously receiving poor input from the cholinergic denervated PPN. 
Since the input from the PPN is detrimental to gait and balance, then output from either of the 
cerebellar nuclei might be “damaged” after relaying in the thalamus, regardless of modulation at 
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the level of the cerebellum. In this case, “damaged” dentate nucleus output (after relaying in the 
thalamus) would reach the dysfunctional basal ganglia and likely be further impaired. Hence, it is 
likely that both the basal ganglia and the PPN are playing a role in gait and balance deficits in 
PD. 
It must be noted that stimulation targeted to the medial cerebellum may not have directly 
influenced the fastigial nucleus, likewise stimulation of the lateral cerebellum may not have 
directly influenced the dentate nucleus. If this was the case, modulation resulting from the 
stimulation may have instead occurred at the level of the cerebellar cortex (whether medial or 
lateral). Instead, activity within the deep cerebellar nuclei may be indirectly affected through 
modulation of Purkinje cell activity within the cerebellar cortex. It is possible that the inhibitory 
stimulation protocol may have induced long term depression in the Purkinje fibres, whereupon a 
decrease in the net inhibitory drive from the Purkinje fibres may have indirectly modulated 
activity in the deep cerebellar nuclei.  
Clinical Implications 
 
Dopaminergic loss in the striatum and dysfunction of the basal ganglia have been found 
to be more strongly linked with symptoms of bradykinesia and rigidity, and less associated with 
the generation of tremor[27]. The addition of the current evidence, suggests that over-activity in 
the cerebellum may be involved in resting tremor in PD[27,28,34] but not influencing gait and 
balance deficits, may help to explain why these symptoms are not very responsive to 
dopaminergic replacement therapy. Given that dopaminergic replacement is the current gold 
standard for treating motor symptoms in PD[2–4], a better understanding of how to manage 
symptoms that are not responsive to pharmaceutical therapy is crucial.  
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The current study provides evidence that an inhibitory rTMS protocol has the potential to 
improve resting tremor symptoms in tremor-dominant individuals with PD. The advantages of 
using rTMS as a treatment is that the procedure is non-invasive, not painful and requires little 
time per visit. This method of stimulation, when applied over repeated sessions, has the ability to 
induce changes in the cerebellum that last days to weeks beyond the period of stimulation [6,7]. 
It is also important to note that the improvements in resting tremor did not come at the cost of 
detriment to other symptoms, specifically gait and balance.  Further understanding of the 
mechanisms underlying the involvement of cerebellar over-activity in tremor provides promise 
for the development of a treatment for tremor in PD.  
Future Directions 
With the evidence that stimulation of the lateral and medial cerebellum improved tremor 
symptoms, a follow-up study with a sample including only tremor-dominant PD participants is 
warranted. It would be important to limit study participation to tremor-dominant individuals to 
increase statistical power and make the results more clear; measuring the effects of the 
stimulation on tremor in an individual which does not experience tremor would not be possible. 
Replication of results with a larger tremor-dominant sample size would strengthen the evidence 
supporting cerebellar involvement in resting tremor. It would also be important to assess how the 
effects of stimulation may differ when participants are in their OFF medication state. Since 
tremor responds variably to dopaminergic replacement, assessment of individuals in the OFF 
state would allow the assessment of changes to tremor at an individuals’ worst severity. In 
addition, this would help to disentangle what might happen to the modulated output from the 
lateral cerebellum upon relay in the basal ganglia. If tremor was improved to the same degree in 
the OFF medication state, then it may be possible the output from the lateral cerebellum is either 
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not relaying in the basal ganglia, or dopaminergic loss and basal ganglia dysfunction may not be 
strongly related to tremor.  
Anecdotal evidence from participants in the current study who experienced a relief in 
tremor reported improved symptoms beyond the period of assessment (some reporting up to 12 
hours of improvement). This is an unusual finding, given that stimulation effects are expected to 
last for a length of time about equal to that of the period of stimulation. The next logical step 
would be to also investigate the 24-hour effects of stimulation with an accelerometer which 
could be worn at home. A better understanding of the temporal profile of the stimulation effects 
would help to increase understanding of how long the stimulation effects are able to modulate 
synaptic activity in the cerebellum. Knowing how long the stimulation effects last at the 
subcortical level would aid in the design of a multiple session rTMS protocol. Repeated sessions 
of stimulation applied within the correct time period would allow for the effects of the 
stimulation to accumulate. It is possible that the cumulative effects of stimulation may interact 
with the mechanisms of cortical plasticity, and prolong the period for which LTD, and thus 
symptom improvement, lasts. A review by Fregni et al., demonstrated effects following an acute 
session of stimulation to be predictive of long-lasting effects following repeated sessions of 
stimulation [16]. For example, if there are not immediate motor benefits after stimulation, then 
effects following repeated sessions should not be expected. Alternatively, when motor benefits 
do exist following one session of stimulation, cumulative effects can be hypothesized following 
multiple sessions of stimulation. Given the clear benefits to tremor following the current 
protocol, when paired with the proper repeated stimulation schedule, it can be hypothesized that 
long-lasting benefits resting tremor could occur.  
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The current study was an important step in the direction towards gaining understanding 
of the contribution of the cerebellum to PD motor symptoms. It also sheds light on the possibility 
of investigating further rTMS treatments for the improvement of resting tremor, an otherwise 
poorly dopaminergic responsive motor symptom in PD.   
Limitations 
 
One limitation of this study from a statistical perspective, was that randomization was 
done only to assign participants to groups (i.e. medial, lateral or sham), and thus, there was an 
unequal number of tremor-dominant and PIGD participants in each group. Block randomization 
could have been done to ensure an equal distribution of PD sub-types within each group. 
Nonetheless, groups were matched in terms of symptoms severity (in addition to tremor severity) 
despite slightly differing in PD sub-type proportions.  
The absence of individual magnetic resonance (MR) images for participants was a 
limitation in the study that was controlled in a manner based upon the best methods used in 
previous research. There exists neuronavigation software which enables the upload of participant 
MR images; this would allow TMS targets to account for individual anatomical anomalies. In 
this case, access to individual MR images was not possible. Neuronavigation was still utilized, 
and a target was still created in the program to represent the hot spot for the first dorsal 
interosseous (FDI) muscle. This was a manual process involving systematic movement of the 
stimulation coil, and monitoring of EMG activity in the FDI muscle. The program was important 
in providing a target so that the coil could be maintained in the correct location when the resting 
motor threshold protocol was done.  
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MRI-guided neuronavigation can also be advantageous for determining cortical and sub-
cortical locations that do not evoke motor responses in the same way the motor cortex does. Two 
stimulation sites were used in this study: the vermis (fastigial nucleus) and the lateral cerebellum 
(dentate nucleus). Previous studies have shown the vermis to be located beneath the inion, thus, 
this target was located through surface palpation. The lateral cerebellum has been reliably 
located to be three centimetres lateral and one centimetre inferior to the inion[50,70]; this 
location was carefully measured for individuals who received stimulation targeted at the dentate 
nucleus.  
The final way in which individual MR images could have been utilized in this study was 
to perform depth calculations to determine stimulation intensity. Depth calculations are 
important because the thickness of the skull is greater over the cerebellar area than it is over the 
motor cortex. Since the resting motor threshold is determined by applying stimulation over the 
motor cortex, the depth calculation would serve to account for the greater impedance of the 
magnetic pulses when passing through the thicker bone above the cerebellum. Previous studies 
which were not able to perform depth calculations applied rTMS over the cerebellum at an 
intensity of 120% of the resting motor threshold to ensure the pulses were strong enough to reach 
the same depth in the cerebellum[52,71]. These principles were also applied in the current study. 
It is important to note that by using a standardized percentage of resting motor threshold to set 
the stimulation intensity for the repeated pulses is advantageous, since the intensity is a relative 
number based upon individual participants’ cortical excitability levels.  
Though the use of individual MR images would have added an additional layer of 
precision to the study protocol, the methods used to compensate have been validated in previous 
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studies. Given that quantifiable effects on tremor were found following rTMS, it can be 
concluded that the methods utilized were appropriate.  
A few limitations exist within the outcome measures that were chosen. In terms of the 
outcomes measure used for tremor, it would have been beneficial to have the inability to extract 
kinematic parameters from the motion sensory individually for analysis as opposed to the output 
of only a composite score. Understanding whether the improvement in resting tremor was driven 
mainly by a decrease in tremor frequency or a change in tremor amplitude is important from a 
clinical perspective. Irrespective of decreasing tremor frequency, an increase in the amplitude of 
the tremor movements might enable greater functional control of the hands during activities of 
daily living. The Kinesia motion sensor has however been proven to have a strong correlation 
with clinical tremor ratings, in addition to having the granularity to detect changes in tremor 
severity that were not distinguishable by clinician assessment [57].  
Similarly, the Biodex balance platform records postural sway and outputs a composite 
score of average degrees of postural sway in the medio-lateral and anterio-posterior directions 
along with a standard deviation. While this provides a global assessment of postural control 
changes, measurement of postural stability and balance with use of a force plate would have 
allowed more in-depth assessment of balance. The ability to trace postural sway over time, or to 
look at the movement of the centre of pressure might have enabled detection of more finite 
changes in balance following stimulation.  
Conclusion 
 
The current thesis provides evidence to suggest the involvement of the fastigial and 
dentate nucleus in the generation of resting tremor in PD. Following a single session of 
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inhibitory rTMS over either the medial or lateral cerebellum, a reduction in resting tremor was 
found, specifically in tremor-dominant individuals. Concurrent evidence also suggests gait and 
balance deficits in PD to be unrelated to cerebellar over-activity, and supports previous research 
suggesting these deficits may be more related to cholinergic denervation of the PPN and basal 
ganglia dysfunction. Given that tremor, gait and balance symptoms in PD are poorly responsive 
to dopaminergic replacement therapy, furthering the current understanding of how the cerebello-
thalamo-cortical circuit might be influencing these symptoms has the potential to lead to the 
development of novel treatments in PD.  
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Figure 1: Model of cerebellum in Parkinson’s disease 
 
